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1 ABSTRACT 
C. perfringens epsilon toxin (ε-toxin) is a potent heptameric β-pore forming toxin 
secreted by C. perfringens toxinotypes B and D. ε-toxin causes fatal disease in 
livestock populations that is characterised by severe neurological disruption. 
Numerous formaldehyde based veterinary vaccines against ε-toxin are 
available. However, these suffer from poor immunogenicity and side effects and 
are unsuitable for human use. Recently, ε-toxin has also been proposed as an 
aetiological agent for multiple sclerosis following the isolation of C. perfringens 
Type B in a multiple sclerosis (MS) patient. Further research has identified ten 
times greater ε-toxin immunoreactivity in MS patients compared to healthy 
controls. The aim of this study is to investigate two areas. Firstly, ε-toxin’s beta-
octyl glucoside (BOG) binding site was analysed for cytotoxicity against 
Chinese hamster ovary cells (CHO) expressing the putative myelin and 
lymphocyte (MAL) receptor using seven site directed mutants (V72A, V72F, 
F92A, T93A, V166A, V166F, A168F). The V72F, V166F and the A168F mutants 
demonstrate strongly reduced toxicity in CHO-hMAL cells and show promise as 
potential recombinant vaccine candidates against ε-toxin. Secondly, sera from 
control, CIS and MS patients were screened for ε-toxin immunoreactivity by 
investigating if sera conferred cytotoxic protection to CHO-hMAL cells incubated 
with ε-toxin. However, high sera lactate dehydrogenase (LDH) enzyme activity 
distorted experimental results. Consequently, it remains unclear if the sera 
exhibit immunoreactivity towards WT ε-toxin. The results suggest that fresh 
standardised sera samples should be used in future to mitigate this issue by 
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6 OBJECTIVE 
This report is submitted as a dissertation for the degree of Masters by Research 
in Biosciences. The objective of this report is to present the work and findings 
from the investigation of two topics, namely: 
1) The development of a next generation veterinary vaccine against ε-
toxin  
2) Investigating the immunoreactivity of multiple sclerosis patients to ε-
toxin 
The investigation of these topics was undertaken by considering them as two 
separate projects. These are named Project 1 and Project 2 in this report. 
The report is structured as follows: 
• Introduction         Section 7 
• Project 1 – ε-toxin Toxin Mutagenesis   Section 8 
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7 INTRODUCTION 
This section provides a comprehensive summary of current knowledge 
regarding the C. perfringens bacterium, the different toxins it can produce, and 
a focussed review of ε-toxin. 
7.1 CLOSTRIDIUM  PERFRINGENS 
C. perfringens, belonging to the Clostridium genus, is a non-motile Gram-
positive spore-forming bacillus found ubiquitously in the environment. It is 
closely related to several other pathogenic bacteria including Clostridium 
botulinum, Clostridium tetanii and Clostridium difficile. Consistent with other 
members of the Clostridium genus, C. perfringens can exist as a vegetative cell 
or as a dormant spore. The vegetative cells of C. perfringens are rod shaped, 
demonstrate pleomorphism and normally exist in small chains [1]. These cells 
demonstrate a similar morphology to other Gram-positive bacteria including a 
thick peptidoglycan cell membrane containing capsular polysaccharides, and an 
inner cytoplasmic lipid membrane. As a vegetative cell, C. perfringens grows as 
an obligate anaerobic mesophile with optimal propagation achieved at 37°C in 
environments containing little to no oxygen. C. perfringens bacteria have been 
isolated in a variety of anoxic environments including soil, sewage and marine 
sediment [2].  However, the bacterium has also been isolated in the intestinal 
tracts of humans and animals and is known to be present in a variety of food 
products [1][3]. Under harsh environmental conditions, C. perfringens can 
transition to exist as a highly resistant spore [4]. These spores demonstrate high 
thermal, ultraviolet and desiccation tolerances enabling the C. perfringens 
bacterium to survive for long periods in hostile environments that are unsuitable 
for vegetative growth [4]. The prevalence and durability of these spores, 
particularly in food products, has resulted in the recognition of C. perfringens as 
a serious food safety concern [5]. Furthermore, the ubiquity of C. perfringens in 
these environments has firmly established it as one of the most widely spread 
pathogens in existence. 
The virulence of C. perfringens is attributed to its arsenal of seventeen different 
secretory exotoxins [6]. Four of these toxins are known to exhibit lethal 
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properties and are considered major toxins. The different strains of C. 
perfringens demonstrate substantial variability in the array of toxins that they 
can secrete. Consequently, C. perfringens classification is divided into five 
serotypes (A-E) based on the secretion profile of the four major toxins: alpha, 
beta, epsilon and iota [6]. The five serotypes are listed in Table 7-1. 
 TOXIN 
Type Alpha Beta Epsilon Iota Enterotoxin 
A + - - - ± 
B + + + - ± 
C + + - - ± 
D + - + - ± 
E + - - + ± 
+ Type produces this toxin 
- Type does not produce this toxin 
± Some strains of that type produce this toxin 
Table 7-1 - Secretion profiles of alpha, beta, epsilon and iota toxin by C. 
perfringens serotypes A, B, C, D and E. [7] 
The variety of different toxins secreted by C. perfringens is essential in its ability 
to perform as a pathogenic organism. The toxins all show structural variability 
and differences in their ability to cause disease. Subsections 7.1.1 to 7.1.5 
investigate the main toxins secreted by C. perfringens and their roles in human 
and animal disease. 
7.1.1 C. perfringens - Enterotoxin  
The Clostridium perfringens enterotoxin (CPE) is a 35 kDa single polypeptide 
toxin that currently ranks as the third leading cause of food poisoning in the 
United Kingdom, United States and Canada. In the United States, the bacterium 
is responsible for approximately 966,000 gastroenteritis cases each year with 
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an estimated annual economic loss of $400 million [1][8][9]. CPE is primarily 
associated with outbreaks at catering institutions where large quantities of food 
are prepared [10]. The disease is normally initiated through inadequate food 
preparation and results in isolated outbreaks typically affecting 50-100 people 
[1]. These gastroenteritis outbreaks are caused by the C. perfringens Type A 
strain, although CPE positive Type C and D strains have also been reported 
[11]. Despite the prevalence of C. perfringens, only an estimated 5% of the 
global C. perfringens population contain the cpe gene encoding the enterotoxin 
[12][13]. The cpe gene can be located either chromosomally or on a plasmid. 
An estimated 70% of C. perfringens Type A isolates contain a chromosomal 
copy of the gene with the remainder carrying the cpe gene on a 70-75kB 
conjugative plasmid [6][8][14]. CPE’s protein structure was revealed following 
analysis from two studies in 2010 (Figure 7-1) [8][15][16]. This identified that 
CPE contained two domains; a C-terminal receptor binding domain and an N-
terminal domain that controls oligomerization and pore formation [8].  
 
Figure 7-1 - The two-domain protein crystal structure of the CPE toxin [8] 
[15].  
CPE related gastroenteritis is facilitated by the germination of C. perfringens 
Type A spores in food products following completion of the cooking process. C. 
perfringens spores have been isolated in a variety of food products including 
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spices, condiments, fish, poultry, beef and prepared dishes [1]. The durability of 
these spores in thermogenic environments enables them to survive most 
cooking processes. Temperatures ranging between 12°C-60°C promote the 
germination of C. perfringens spores and subsequent vegetative growth. This 
temperature range is frequently used by the catering industry in warm food 
holding areas ready for serving [17]. Consequently, cooked foods left in heated 
holding areas for extended time periods risk initiating a C. perfringens 
gastroenteritis outbreak [5].  
If large quantities of contaminated food are ingested, some C. perfringens Type 
A bacteria can survive digestion and translocate to the intestines. These 
bacteria proliferate within the gut before re-entering sporulation and initiating 
CPE production. Following sporulation, the C. perfringens spores lyse releasing 
CPE [8]. The CPE is released into the intestinal lumen where it binds to claudin 
proteins located at epithelial tight junctions in the intestines. The claudin protein 
structure contains two extracellular loops ECL1 and ECL2 that are critical for 
CPE binding to the epithelial cell membrane [18][19]. CPE binding to the claudin 
proteins results in the formation of a non-cytotoxic 90 kDa complex [20]. Several 
of these complexes oligomerise to form a larger 450 kDa prepore complex 
named CH-1 [20]. The CH-1 complex contains beta hairpin loops that assemble 
into a beta barrel that creates a pore within the membrane [21]. Pore formation 
within the intestinal cell membrane leads to fluid imbalance and the influx of 
calcium that results in cell death.  The disease is characterised by symptoms of 
diarrhoea and abdominal cramps in the affected patient that typically last 24 
hours [22][23]. With extended time the toxin forms an even larger 600 kDa 
complex named CH-2, however, the role of CH-2 in cytotoxicity is not fully 
understood [8][24].  
CPE is also known to cause acute intestinal damage in other mammalian 
species including rabbits, cats and dogs. C. perfringens is a normal commensal 
organism in the microflora of these species and has been reported in 80% of 
dogs [25]. Disease is normally initiated by microfloral disruption that enables C. 
perfringens to become competitively dominant. This can be attributed to 
changes in diet, antibiotic administration, stress or coinfections in the intestines 
[26]. CPE related disease is frequently self-limiting in these animals although 
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some rare cases of suspected fatalities have been reported [27]. 
7.1.2 C. perfringens – Alpha Toxin 
Alpha toxin is a 43 kDa sized lethal exotoxin produced by the C. perfringens 
bacterium with a reported lethal dose of 40 ng/ml [28][29][30]. Alpha toxin is 
encoded by the chromosomally located cpa gene that is located in a highly 
stable area of the bacterial chromosome [31]. Alpha toxin gene expression is 
regulated by the VirR/VirS two component system; however, the environmental 
signalling factor stimulating cpa expression is currently unknown [32]. Alpha 
toxin is produced by all five C. perfringens toxinotypes with C. perfringens Type 
A producing the largest quantity of alpha toxin (Table 7-1). Enzymatically, alpha 
toxin demonstrates both phospholipase C and sphingomyelinase activities [33]. 
This enables alpha toxin to cleave phospholipids and sphingolipids commonly 
found within eukaryotic cell membranes to initiate cell lysis. Consequently, high 
concentrations of alpha toxin result in extensive cell lysis from cell membrane 
damage [17]. The alpha toxin crystal structure was first established in 1998 and 
revealed that the toxin is structurally divided into two domains [34]. This is 
presented in Figure 7-2. 
 
Figure 7-2 - The two domain protein crystal structure of the Clostridium 
perfringens alpha toxin [35].  
1) The N-terminal domain contains the residues responsible for alpha 
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toxin’s phospholipase C, sphingomyelinase and cytotoxic activities 
[36]. The domain consists of nine alpha helices and zinc binding 
ligands that are essential for alpha toxin’s toxicity [33]. The binding 
of zinc ions to these ligands helps to support the structural integrity 
of alpha toxin and assists in its phospholipase C activity [17][37]. 
Treatment of the N-terminal domain with ethylenediaminetetraacetic 
acid (zinc chelating agent) abolishes alpha toxin’s phospholipase C, 
sphingomyelinase and cytotoxic activities, which strongly suggests 
that the zinc ions are essential for alpha toxin’s functionality. Further 
studies have indicated that the zinc binding ligands may also serve 
as part of alpha toxin’s catalytic site [33][37][38]. Previous research 
has identified that the enzymatic activity of the N-terminal domain is 
clearly required for alpha toxin to elicit toxicity [36]. However, by 
itself, the N-terminal domain is insufficient to cause disease which 
suggests that the activity of the C-terminal domain is also required 
for alpha toxin to initiate toxicity [17].  
2) The C-terminal domain also known as PLAT (Ploycystin-1 
Lipoxygenase, Alpha-toxin) functions as a membrane binding 
domain [33]. The PLAT structure is commonly found in membrane 
associating proteins and consists of an eight stranded antiparallel 
beta sandwich formed from beta sheets [33]. Current evidence has 
identified that the C-terminal domain is involved in membrane 
interactions; however, the C-terminal domain demonstrates no 
cytotoxic or cytolytic effects. Instead, the C-terminal domain appears 
to facilitate binding of alpha toxin to host cells that enables the N-
terminal domain to elicit toxicity. The molecular action of the C- 
terminal domain is facilitated by several tyrosine residues and a 
phenylalanine residue that are critical for membrane binding 
[39][40]. Furthermore, the C-terminal domain contains calcium-
binding ligands that are considered essential for alpha toxin’s activity 
[41]. These calcium ions facilitate structural changes within the C-
terminal domain exposing hydrophobic residues which play a key 
role in phospholipid binding to host cell membranes [17]. Once 
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associated with the host cell membrane, these calcium ions form 
bridges which enable hydrophobic residues to insert into the cell 
membrane in order to initiate cytotoxicity [17]. 
Alpha toxin is one of the primary etiological agents of gas gangrene also 
referred to as clostridial myonecrosis in humans. Gas gangrene is an 
aggressive infection in which healthy tissue is rapidly destroyed resulting in 
mass necrosis and gas accumulation that can be fatal. Historically the disease 
was associated with battlefield injuries but has also been connected to natural 
disasters and, in recent years, intravenous drug use [17]. Gas gangrene is 
primarily caused by C. perfringens that accounts for 80% of cases [42]. The 
disease is initiated following deep lacerations and crush type injuries that 
facilitate the introduction of C. perfringens into deep tissues [42]. Research into 
the disease has identified that alpha toxin stimulates platelet, fibrin and 
neutrophil aggregation by interacting with the platelet fibrinogen receptor 
glycoprotein IIb/IIIa. [43]. These aggregates occlude blood vessels that obstruct 
local and regional blood flow in neighbouring tissue [43]. The reduced blood 
flow promotes an anaerobic environment that is believed to facilitate the spread 
of C. perfringens. Additional studies have identified that polymorphonuclear 
leukocytes accumulate along the endothelial layer of blood vessels and fail to 
migrate into the periplasmic space [43]. This appears to be due to the up 
regulation of intercellular and endothelial adhesion molecules including E-
selectin and ICAM-1 [44].  Alpha toxin is cytolytic towards leukocytes that may 
also contribute to the reduction of inflammatory immune cells to these infected 
tissues [45]. These data suggest that alpha toxin may also be able to influence 
the host’s immune response to assist the spread of infection [17][46]. The 
disease is also present in calves, horses and piglets and requires similarly 
harsh surgical and medical techniques to ensure survival [47][48]. In all these 
forms of disease, alpha toxin is widely recognised as the primary mode of 
virulence.  
7.1.3 C. perfringens – Beta Toxin 
Beta toxin is a 34 kDa sized lethal toxin produced by C. perfringens [49]. The 
cpb gene located on a C. perfringens plasmid encodes the toxin with expression 
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controlled by the VirR/VirS two-component system [50]. Beta toxin exhibits 
dermonectrotic effects but demonstrates no haemolytic properties. Unlike other 
C. perfringens toxins, it is highly sensitive to environmental conditions and can 
be quickly degraded by heat and trypsin digestion [51]. Consequently, beta 
toxin can only initiate disease under specific environmental conditions. 
However, individuals subject to a diet rich in trypsin inhibitors are more 
predisposed to beta toxin disease [51]. Sequence alignments identify that beta 
toxin shows significant structural similarity with S. aureus alpha toxin indicating 
that beta toxin may belong to the β-pore forming toxin family [52]. The structure 
of beta toxin can be seen in Figure 7-3: 
 
Figure 7-3 - The two domain protein crystal structure of the C. perfringens 
beta toxin [53].  
 
Beta toxin is produced by C. perfringens toxinotypes B and C. Both strains can 
infect animals causing haemorrhagic enteritis and diarrhoea in domesticated 
livestock species [52][54]. However, Type C infections are recognised as more 
prolific in neonatal animals [55].  Beta toxin has been identified as the etiological 
agent of the disease that is characterised by severe mucosal necrosis on the 
small intestines [50]. In animals, beta toxin infection corresponds to a high 
mortality rate approaching 100%, resulting in significant economic losses [54].  
C. perfringens Type C has also been linked to necrotizing enterocolitis in 
humans through the action of beta toxin. This disease, also referred to as 
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pigbel, is not found in western countries. However, the disease was reported in 
the Highland of Papua New Guinea in 1973, and an outbreak recorded in 
Germany following the end of World War Two [56][57]. In both cases, the 
disease was attributed to beta toxin after the sudden consumption of a protein 
rich diet following a long period of ingesting a low protein diet [52]. Infected 
individuals possessed lower intestinal trypsin levels indicated they were at 
higher risk of beta toxin infection. The pigbel disease has a reported mortality 
rate of 35-40% and results in severe mucosal necrosis, inflammation and 
haemorrhaging within the small intestine that usually requires surgical treatment 
[52].  
Beta toxin’s molecular mechanisms of disease are largely unknown due to a 
lack of susceptible cell lines for in vitro experimentation [52]. However, beta 
toxin has been shown to bind to vascular endothelial cells at lesion sites and 
initiates disease through pore formation [58][59]. Pore formation is initiated by 
beta toxin monomers binding to a currently unknown receptor that is believed to 
localise on lipid raft microdomains on susceptible cells [60]. Binding is followed 
by rapid oligomerization into a heptameric pre-pore on the cell surface [51]. 
Oligomerisation also protects beta toxin from trypsin digestion by burying trypsin 
targets into the toxin structure [51]. The beta toxin oligomer inserts into the host 
cell membrane creating a pore that initiates ion uptake into affected cells. This 
ion disruption results in morphological changes and cell death through 
programmed necrosis [51][61].  
Much remains unknown regarding the pathogenesis of beta toxin. 
Consequently, more research is required to elucidate the molecular 
mechanisms of beta toxin mediated disease. Fortunately, beta toxin disease is 
considered very rare in the world and can be easily avoided by ensuring basic 
food hygiene, good dietary intake and correct cooking practices. 
7.1.4 C. perfringens – Iota Toxin 
Iota toxin, first described in 1943, is produced solely by C. perfringens 
toxinotype E [62]. It exhibits lethal properties that are associated with enteric 
disease in animals. Most notably, Iota toxin has been linked to antibiotic 
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associated enterotoxemia in rabbits and calves, but has rarely been observed in 
other domesticated livestock [63]. The disease is typically characterised by 
diarrhoea, haemorrhages and oedema in affected animals and can result in 
sudden death [63].  
Structurally, iota toxin is composed of two unlinked and immunologically distinct 
proteins Iota-A and Iota-B that are encoded on a plasmid by the iap and iab 
genes respectively [64][63].  The 47 kDa Iota-A protein confers the toxin’s 
enzymatic activity while the 81 kDa Iota-B protein facilitates cellular binding and 
entry of Iota A into host cells [64]. Both Iota toxin proteins are synthesised and 
secreted during exponential phases of C. perfringens growth. However, trypsin 
proteolytic digestion is required to activate both proteins [65]. Alone, these 
proteins are non-toxic, but together Iota-A and Iota-B exhibit lethal cytotoxic 
properties. 
Following secretion, the C-terminal domain of the Iota-B binding protein 
attaches to an unknown receptor found on lipid rafts on the cell surface [62]. 
Iota-B then oligomerises into a non-toxic heptamer, which facilitates the 
formation of ion permeable channels in the cell membrane [66]. The Iota-A 
protein then interacts with Iota-B’s exposed N-terminal domain. This interaction 
facilitates the internalisation of Iota-A into the target cell by receptor-mediated 
endocytosis. Following this, it is believed that Iota-A is then transported into the 
cytosol via endosomal trafficking [62]. Once internalised into the cytosol, Iota-A 
then adenosine diphosphate ribosylates skeletal muscle alpha actin and non-
muscle beta/gamma actin at arginine-177 [67][68]. The ribosylation inhibits actin 
polymerisation preventing the formation and extension of cytoskeletal filaments 
[69]. This action by Iota-A results in the breakdown of the cell’s cytoskeleton 
causing cell rounding, intoxication and cell death [62]. 
Iota toxin disease is considered rare and little research has been undertaken to 
investigate the molecular mechanisms of Iota toxin thoroughly [63]. 
Consequently, the pathogenesis and molecular interactions of Iota toxin are 
poorly understood. However, the C. perfringens Type E toxinotype that 
produces Iota toxin is not prevalent in the environment. As a result, Iota toxin is 
 
 
Page | 25 
 
not recognised as a significant public health or animal health concern.  
7.1.5 C. perfringens – ε-toxin  
ε-toxin is a 32.9 kDa sized heptameric β-pore forming toxin synthesised by C. 
perfringens toxinotypes B and D [70][71]. ε-toxin has a reported intraperitoneal 
lethal dose of 1.2 ng/kg in mice [72]. This makes ε-toxin the most potent toxin 
secreted by C. perfringens and the third most potent toxin known to man, 
preceded only by the C. botulinum and C. tetani neurotoxins [73]. As a result of 
its marked toxicity, ε-toxin has gained attention from governments around the 
world who recognise it as a bioterrorism threat. Currently, ε-toxin is registered 
as a category B biological agent, the second highest bioterrorism security 
priority recognised by the Centre of Disease Control and Prevention [71]. 
Pathologically, ε-toxin is a major cause of morbidity and mortality in domestic 
livestock, most notably in sheep and goat populations around the world [71]. 
Clinical symptoms of ε-toxin are dose dependent and occur rapidly, normally 
within minutes to hours after exposure [74]. ε-toxin immunogenicity has recently 
been described in MS patients suggesting that ε-toxin may be the etiological 
agent behind the condition [75].  
C. perfringens ε-toxin is genetically encoded by the etx gene that is located on 
plasmid vectors. In C. perfringens toxinotype D, the etx gene can be harboured 
by at least five different plasmids that vary from 48 to 110 kbp [76][77]. Two of 
these plasmids can be conjugated between different C. perfringens strains [76]. 
This distribution and acquisition of new plasmids enables C. perfringens strains 
to quickly change toxinotypes, potentially as an adaptive response to changes 
in their environment. In contrast, Type B harbours the etx gene on a single 65 
kbp plasmid [78]. The upstream promoter regions between the etx gene 
expressed in Type B and D are dissimilar suggesting that ε-toxin expression is 
regulated differently between these different toxinotypes [79][80]. Etx gene 
sequencing, cloning and expression were first successfully completed in 1992 
and have facilitated the use of recombinant deoxyribonucleic acid (DNA) 
technologies to further investigate ε-toxin [70]. This has been of particular 
importance in the context of vaccine development that dominates current 
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research into ε-toxin. The structure of ε-toxin can be seen in Figure 7-4. 
 
Figure 7-4 - The three domain protein crystal structure of C. perfringens ε-
toxin [81].  
As seen in Figure 7-4, ε-toxin possesses a highly elongated structure that 
consists of three domains that are critical in mediating ε-toxin’s pathological 
function: 
1) Domain I – consists of a large α-helix followed by three shorter 
helices [71]. Domain I appears to be critical for ε-toxin’s initial 
interaction with host cells and mediating ε-toxin’s binding to 
receptors [81].  
2) Domain II – consists of a β-sandwich containing a two-stranded 
sheet [71]. Domain II has been identified as ε-toxin’s pore-forming 
domain with an amphipathic sequence believed to mediate ε-toxin’s 
membrane insertion and pore forming capabilities [71]. Domain II 
has also been implicated in ε-toxin’s oligomerisation, and 
stabilisation. The Ser124 and Thr143 residues appear to be 
important in mediating these characteristics [81]. 
3) Domain III – consists of a β-sandwich. This domain contains ε-
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toxin’s cleavage site that is removed during proteolytic activation 
[71]. Functionally, domain III is believed to control ε-toxin’s monomer 
interactions that enable it to oligomerise into a heptamer [71]. It 
contains the only parallel strand in the structure.  
As seen in Figure 7-5, ε-toxin demonstrates similar characteristics to a range of 
bacterial pore forming toxins. In particular, it shares strong structural anaology 
to the Aeromonas aerolysin toxin despite only sharing 14% sequence homology 
[82]. The aerolysin toxin contains an additional domain for interacting with target 
host cells that is absent in ε-toxin. ε-toxin also demonstrates structural similarity 
to many other aerolysin-like toxins including the Laetiporus suphureus lectin 
toxin, Bacillus thurinigiensis parasporin-2 toxin and C. septicum’s alpha toxin 
[79]. However, in all cases, ε-toxin demonstrates far greater potency with 
lethality at least 100 times greater in mice [71].  
 
Figure 7-5 - Illustrates the X-ray crystallography three domain protein 
structures of the L. sulphureus lectin, B. thurnigiensis Parsporin-2, C. 
perfringens ε-toxin and the four domain A.hydrophila aerolysin β-pore 
forming toxins [79]. The figure shows the putative membrane insertion 
amphipathic loops in red.  
ε-toxin is secreted by the B and D toxinotypes of C. perfringens. Similar to other 
C. perfringens toxinotypes, Types B and D are both found in soil and sediment 
environments but can also be found in low numbers (<103 bacteria g-1 ) in the 
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digestive tracts of pathologically associated animals [83]. Both toxinotypes 
represent major causes of disease in domestic livestock; however, the Type D 
toxinotype causes more ε-toxin induced infections. Type B is the etiological 
agent of dysentery in new-born lambs and is also responsible for 
enterotoxemias and enteritis cases in calves, foals and piglets [71]. The Type D 
toxinotype is found globally and is responsible for the fatal enterotoxemias of 
goats, sheep and new-born lambs [71]. Type D disease is most common in 
rapidly growing lambs, less frequent in sheep and goats and occasionally in 
other species [71]. In both Type B and D infections, ε-toxin is considered to be 
the main mode of virulence and lethality in affected animals. Consequently, 
these sometimes rapidly fatal diseases in domestic livestock populations can 
lead to significant economic and agricultural losses.  
Both C. perfringens Type B and D can reside naturally in low number in the 
microfloral environment of ruminant animals without damaging the host. 
Disease is initiated when C. perfringens Types B and D are stimulated to 
produce ε-toxin in the intestines of the host animal. This is normally associated 
with the overgrowth of these bacteria above a threshold of >106 bacteria g-1 
[71]. A variety of factors can stimulate the C. perfringens bacteria to transition to 
a pathogenic organism. ε-toxin producing C. perfringens can rapidly proliferate 
in the digestive tracts of new-born animals, whereby the microflora that 
supresses C. perfringens colonization is undeveloped and non-functional. This 
is particularly common in the case of C. perfringens Type B lamb dysentery that 
can occur within the first few days of life [71]. The overconsumption or sudden 
transition to a carbohydrate rich diet is associated with the proliferation of C. 
perfringens that causes enterotoxemia in older animals [71][79]. The sudden 
influx of undigested carbohydrates such as starch distresses the local microflora 
and serves as excellent growth substrate for C. perfringens [71]. A variety of 
other factors have been linked to the development of ε-toxin disease in animals 
including; parasitic infections, pregnancy, tranquiliser use and antibiotic 
consumption [73][84].  
Acute forms of ε-toxin disease in animals commonly involve neurological 
symptoms including violent convulsions, ataxia, lateral recumbency, cerebral 
swelling and coma [71]. Non-neurological symptoms include laboured 
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breathing, high blood pressure and oedema of various organs. Histological 
patterns between animal species can vary considerably. For example, sheep 
are known to suffer relatively greater brain damage compared to goats, which 
suffer greater intestinal and colonic damage through lesion formation [73]. The 
contrasting pathologies of ε-toxin in different animal species may be explained 
by differences in bacterial growth kinetics between different animal species [85]. 
For example, micro-environmental differences between animals possessing four 
chambered stomachs and linear digestive systems will invariably impact the 
growth of C. perfringens and the subsequent production of ε-toxin [85]. 
However, although ε-toxin’s pathology varies between animal species, some 
symptoms including central nervous system (CNS) damage are observed 
consistently between all infected animals species [73]. 
The symptoms of ε-toxin disease develop quickly, usually within minutes to a 
few hours following exposure, and are rapidly fatal. Older animals typically 
develop a more chronic form of the disease referred to as Focal Symmetrical 
Encephalomalacia (FSE) that is commonly observed in sheep [71]. A recent 
FSE case was reported in a Brazilian goat population that demonstrated 
neurological symptoms, blindness and recumbency up to fourteen days [86]. 
Post-mortem examinations reveal extensive systematic damage in infected 
animals with ε-toxin disease present in multiple organs including the heart, 
lungs, liver, stomach and brain [73]. ε-toxin most notably accumulates 
throughout the kidneys, except in the medulla and proximal tubes [81]. ε-toxin 
has also been reported in bladder epithelial cells. The effects of ε-toxin 
accumulation in animal kidneys are also clearly evident in post-mortem 
examinations. Pulpy kidney disease is typically observed shortly after the 
animal has died from Type D enterotoxemia, and is characterised by the post-
mortem swelling and autolysis of the kidneys [73][87]. The high ε-toxin activity in 
the kidneys during C. perfringens infections may explain why the few 
discovered cell lines susceptible to ε-toxin are from canine, mouse and human 
kidneys. However, it has also been suggested that ε-toxin’s apparent affinity to 
the kidneys may be related to renal function. It has been proposed that the 
kidneys deliberately absorb ε-toxin in an attempt to filter out and reduce toxin 
levels in the bloodstream, and to mitigate harmful effects in other organs 
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[81][87]. However, this theory has not been proven.  
Terminal phases of ε-toxin disease are characterised by severe neurological 
disorders in infected animals. This is induced by ε-toxin’s ability to rapidly 
disrupt the blood brain barrier increasing vascular permeability in order to 
initiate neurological disease. The effects of ε-toxin on the blood brain barrier are 
well described, however, the mechanism by which ε-toxin induces permeability 
changes to the blood brain barrier is not fully understood [88]. After bypassing 
the blood brain barrier, ε-toxin binds to multiple brain structures including the 
hippocampus, thalamus, striatum, olfactory bulb, colliculi and cerebral white 
matter [81]. In mice, the toxin most notably associates with the cerebellum, 
however, immunofluorescence of murine brain slices identified that ε-toxin also 
binds to defined regions of the mouse cerebellar cortex [79][89].  
ε-toxin’s cytotoxic activity within the brain has been well characterised through a 
variety of different research studies. This has found that ε-toxin specifically 
targets and kills myelin forming cells within the CNS and demonstrates 
particular affinity for oligodendrocytes [88][90]. However, other cell lines 
including astrocytes, microglia and neurons appear to be insensitive to ε-toxin 
exposure [88]. Further research identified that ε-toxin is unable to bind to 
immature oligodendrocytes indicating that changes in gene expression during 
maturation are required to initiate ε-toxin’s binding [88]. Furthermore, the 
cytotoxic activity of ε-toxin on oligodendrocytes appears to be independent of ε-
toxin’s pore forming capabilities. Experiments using fluorescently labelled 
BAPTA1 probes demonstrated that the probes were retained by 
oligodendrocytes exposed to ε-toxin [91]. This strongly suggests that ε-toxin 
does not form pores within oligodendrocytes. However, studies have identified 
that ε-toxin exposure triggers demyelination in oligodendrocytes that occurs in a 
time and dose dependent manner [88]. This degradation of the myelin sheath 
that protects axons likely explains many of the neurological symptoms 
experienced by animals during ε-toxin infections.  
However, a number of studies indicate that ε-toxin induces neurological damage 
by stimulating neurotransmitter release. For example, ε-toxin stimulates 
dopamine secretion in hippocampal cells, and increases intracellular Ca2+ levels 
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that promote excessive neuronal transmitter firing [81]. In vitro examinations 
also reveal that ε-toxin stimulates glutamate release during oligodendrocyte and 
granule cell binding [81]. Oligodendrocytes and granule cells are known to 
regulate glutamate expression. Therefore ε-toxin damage to these cells may 
correspond to increased glutamate levels by inhibiting regulatory systems [91]. 
Stimulated glutamate release following ε-toxin exposure leads to seizures and 
neuronal damage within the hippocampus [79][92]. These data indicate that 
glutamate is released during direct toxin interactions with granule cells and may 
contribute to the observed neurological symptoms observed in infected animals 
[92]. Post-mortem examinations of affected animal brain tissue, note the 
formation of microscopic and occasionally macroscopic lesions. These brain 
lesions are associated with the localised killing and demyelination activity of ε-
toxin that typically result in the liquefaction of local white matter areas [81][93]. 
The widespread neurological damage inflicted by ε-toxin results in cerebral 
swelling and necrosis within infected animals and is believed to be due to 
multiple factors [73].  
Before the use of commercial vaccines against C. perfringens Type D, more 
lambs died from enterotoxemia than all other diseases combined [73][94]. 
Consequently, significant efforts have been made over the years by the 
veterinary industry to combat ε-toxin related infections in livestock populations. 
A number of commercially available vaccines have been developed to protect 
livestock and are used extensively in veterinary medicine industries around the 
world [71,95]. These vaccines are produced from formaldehyde-inactivated ε-
toxin or C. perfringens culture filtrates. The formaldehyde introduces 
conformational changes within ε-toxin’s structure that detoxify the protein. 
These toxoid vaccines are then filtered to remove the toxic formaldehyde to 
minute levels that are several hundred times lower than the dose required to 
cause harm [96]. These formaldehyde vaccines are inexpensive to produce and 
are used globally in sheep and goat populations. However, the crude design 
and production of formaldehyde vaccines mean that they are too dangerous for 
use in humans [95]. Consequently, no ε-toxin vaccines are commercially 
available for use in humans. Animal vaccination involves two vaccine doses 2-6 
weeks apart followed by either an annual or quarterly boosters in sheep and 
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goats respectively [79][73]. This accounts for the reduced immunoreactivity in 
goats compared to sheep. The vaccine is injected along with an aluminium 
hydroxide adjuvant that helps to promote a stronger immune response [79].  
While cheap to make and use, formaldehyde vaccines have several reported 
setbacks. Firstly, the vaccine formulation is rarely pure. Depending on how the 
vaccine is prepared, it will contain a variety of other bacterial proteins and in the 
case of culture filtrates it can contain whole bacterial cells [79][97]. The lack of 
purification means that there is significant batch variability and immunogenic 
variability between different ε-toxin formaldehyde vaccines. Inflammatory 
responses have been reported in animals following vaccination that have led to 
reduced food consumption [79][98]. Conversely, a study of seven ε-toxin 
formaldehyde vaccines in Brazil identified that only two were sufficiently potent 
[99]. These data indicate that the formaldehyde method of vaccine production 
results in considerable immunogenic variability that is unacceptable for reliable 
immunization. Finally, the formaldehyde used to detoxify proteins is toxic to 
living organisms and therefore has to be removed by filtration. This introduces 
potentially unnecessary risks to producing vaccines with this method that could 
be avoided using other techniques. As a result of these issues, efforts have 
been concentrated on investigating other alternative techniques of vaccination. 
One approach is to use site directed mutagenesis (SDM) to produce genetic 
toxoids of ε-toxin. This produces an attenuated form of the toxin by introducing 
amino acid substitutions. Two genetic toxoids for ε-toxin have been generated 
using isoleucine to cysteine mutations [100]. These mutants significantly reduce 
toxicity in Madin-Darbey Canine Kidney (MDCK) cells by restricting toxin 
insertion and disrupting toxin oligomersation [73]. However, despite these 
advancements the development of a reliable vaccine technology for ε-toxin 
immunization remains one of the biggest challenges facing the veterinary 
industry.  
 ε-toxin’s toxin Production 7.1.5.1
ε-toxin is synthesised as a 32.9 kDa sized protein during exponential C. 
perfringens growth within the host environment [71]. The toxin contains a leader 
sequence that facilitates its transport out of the bacterial cytosol into the 
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extracellular environment [73]. This protein can bind to sensitive cell lines but is 
unable to oligomerise and therefore fails to elicit cytotoxicity. This first inactive 
form of ε-toxin requires proteolytic digestion in order to activate its cytotoxic 
activities [71]. It is therefore referred to as the epsilon prototoxin. Subsequent 
proteolytic digestion can either be completed by trypsin and chymotrypsin host 
enzymes or via C. perfringens secreted λ protease [71]. Proteolytic activation of 
ε-toxin requires the removal of both amino and carboxyl terminal residues from 
the prototoxin. Proteolytic activation removes between 10-13 N-terminal and 22-
29 C-terminal residues depending on the protease catalysing the digestion [81] 
[101]. ε-toxin potency varies depending on which proteases complete the 
digestion. Maximum ε-toxin potency is achieved through the combined 
activation of trypsin and chymotrypsin resulting in the loss of 13 N-terminal and 
29 C-terminal residues [81][102]. ε-toxin digestion results in the formation of a 
28.6 kDa activated mature toxin that is >1000 fold more potent compared to the 
original prototoxin [101]. Removing the C-terminal residues from the prototoxin 
facilitates conformational changes that enable ε-toxin to heptamerise on 
targeted cells and subsequently elicit disease [71]. Recent research has 
identified a C. perfringens Type D strain that uses an intracellular protease to 
activate ε-toxin, which is subsequently released following autolysis of the 
bacterial cell [103]. However, the protease responsible for this activity is 
currently unknown.  
After proteolytic activation, ε-toxin acts locally on intestinal epithelial cells. The 
mechanism of how ε-toxin bypasses the intestinal epithelial layer into the blood 
stream is not currently understood. Transmission electron microscopy studies of 
infected mice and rat intestinal epithelial cells revealed that ε-toxin likely 
increases the permeability of the small intestines by opening mucosal tight 
junctions [79][104]. The opening of these junctions can induce the accumulation 
of fluids and macromolecules into the intestinal lumen leading to diarrhoea [81]. 
This suggests that ε-toxin modulates intestinal permeability to assist its 
absorption into the bloodstream. Research has also suggested that sialidases 
produced by C. perfringens play a crucial role in initiating ε-toxin disease [81]. 
Sialidases are known to assist ε-toxin’s oligomerisation within the intestinal 
environment and may help to expose receptors for ε-toxin on the intestinal 
 
 
Page | 34 
 
epithelial layer [81]. Sialidase activity, which increases when in contact with the 
trypsin enzyme, also plays an important role in facilitating the initial colonisation 
of C. perfringens in the intestines, by promoting adhesion to host cells [105]. 
The absorption of ε-toxin in the intestines is not associated with histological or 
ultrastructural changes to the intestinal epithelium [71]. Furthermore, intestinal 
lesions are not frequently observed in C. perfringens type D enterotoxemia 
cases [71][104]. This suggests that ε-toxin absorption may exploit the 
paracellular pathway by passing through intercellular spaces between intestinal 
epithelial cells to enter the host blood stream [71]. After gaining access to the 
bloodstream the toxin can then be disseminated across the host where it can 
elicit disease in a variety of different organs.  
Research using a rat model identified that ε-toxin targets endothelial cells and 
increases vascular permeability following intradermal injection [106]. This 
appears to be due to direct interactions between ε-toxin and vascular 
endothelial cells [106]. Further experiments using intravenously injected 
fluorescently tagged ε-toxin identified that ε-toxin bound to the luminal surface 
of endothelial cells of most blood vessels [107][108]. Observed necrotic cells 
within the endothelium following ε-toxin exposure suggests that ε-toxin 
decreases the integrity of the endothelial cell layer by killing cells rather than 
exploiting intercellular junctions [106]. The importance of these mechanisms is 
not understood partly because many-cultured endothelial cell lines are 
insensitive to ε-toxin exposure. In fact, ε-toxin demonstrates cytotoxicity in a 
very limited range of cell lines with most research being conducted in MDCK, 
mpkCCDcl4 and human G-402 cell lines [109]. This lack of susceptible cell lines 
may be because cultured cells do not express the appropriate ε-toxin receptor 
when grown in vitro [71][110]. 
In recent years, research has focussed on investigating ε-toxin’s molecular and 
cellular mechanisms of action. Research using MDCK cells has identified that ε-
toxin monomers bind to host cells using a specific receptor that is currently 
unknown [71]. The restricted nature of this receptor results in highly localised 
and concentrated levels of ε-toxin monomers that facilitate this oligomersation 
process [111]. ε-toxin monomers bind to the outside of the host cell and are not 
internalised during the intoxication process [112]. The binding of toxin 
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monomers is accompanied by the formation of a large 155 kDa or 220 kDa 
complex, whereby the toxin monomers oligomerise into a heptamer on the cell 
surface [81][112]. This complex inserts into the host cell membrane forming a 
transmembrane pore that facilitates the passage of molecules up to 1 kDa in 
size [112]. The formation and activity of the pore are understood to be 
temperature dependent [73]. Pore formation induces an increase in the host 
cell’s membrane permeability resulting in a rapid decrease in intracellular 
potassium and an influx in sodium, chloride and calcium ions [71]. Secondary 
effects of ε-toxin intoxication include cytoskeletal dysfunction followed by 
mitochondrial breakdown and disruption to cell monolayers [73]. This is 
characterised by changes in cell morphology including cell swelling and 
membrane blebbing [71]. Ultimately, the cell undergoes rapid cell death through 
necrosis. The signalling cascade initiating this response is not understood but 
may be triggered through adenosine triphosphate depletion or the sudden loss 
of potassium ions [113]. This intoxication process results in lesion formation that 
can be observed in the different organs including the kidneys, lungs and brain 
during ε-toxin disease [81]. 
The lipid environment of targeted cell membranes appears to play a crucial role 
in mediating ε-toxin’s initial binding to host cells. Research has identified that ε-
toxin specifically localises to cholesterol and sphingolipid rich lipid raft 
microdomains on the cell surface [114][115][116]. This strongly suggests that 
the currently unknown ε-toxin binding receptor is located on these lipid raft 
micro domains. Research has shown that both activated and inactivated forms 
of ε-toxin can bind to these lipid rafts, however, inactivated epsilon prototoxin is 
unable to form heptamers to initiate pore formation [73]. Cholesterol levels in 
the lipid rafts are functionally critical in mediating ε-toxin‘s activity, with 
cholesterol depleted lipid rafts demonstrating an inhibitory effect on ε-toxin’s 
oligomerisation [114]. Research using human kidney adenocarcinoma (ACHN) 
cells has identified that the Caveolin 1 and 2 proteins appear to promote 
cytotoxicity by stimulating ε-toxin oligomerisation [117]. ACHN cells devoid of 
the Caveolin proteins result in significantly reduced ε-toxin oligomerisation [73]. 
Consequently, this research provides strong evidence to suggest that the lipid 
composition of host cells appears to play a crucial role in mediating ε-toxin’s 
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receptor access, oligomerisation and pore formation.  
ε-toxin’s binding specificity for specific cell types suggests that it binds to a 
particular receptor. In vivo ε-toxin preferentially binds to brain and kidney cells, 
however, cytotoxicity assays on seventeen different human cell lines identified 
only the G-402 cell lines to be highly susceptible to the toxin [109]. It has been 
documented that some cell lines sensitive to ε-toxin in vivo become insensitive 
when cultured in vitro [82][118]. This is likely due to the changes in receptor 
expression during in vitro cell culturing. This has impeded research aimed at 
investigating ε-toxin’s binding receptor.  
Previous research has shown that ε-toxin can oligomerise on membrane 
vesicles. However, little activity was observed on protein free vesicles 
suggesting that ε-toxin binds to a protein or glycoprotein based receptor [82]. 
Recently, research indicated that the hepatitis A virus receptor one (HAVCR1) 
facilitated ε-toxin binding and cytotoxicity in MDCK cells [119]. HAVCR1 is a 
class one O-linked membrane glycoprotein that can exist in several isoforms. 
The 100 kDa variant of HAVCR1 appears to bind to several tyrosine residues 
(Y29, Y30, Y36 AD Y196) accessible within domain one of ε-toxin to initiate 
binding [119]. Mutating these tyrosine residues prevented ε-toxin binding and 
cytotoxicity in MDCK cells [82]. In particular, replacement of Y30 and Y196 
residues with alanine generated mutants with significantly reduced cytotoxicity 
in MDCK cells. A Y30A-Y196A combined mutant demonstrated a 430-fold 
reduction in cytotoxicity compared to wild type (WT) ε-toxin in MDCK cells [120] 
The mutant was non-toxic in mice and demonstrated potential for forming the 
basis of a recombinant vaccine against enterotoxemia in ruminant animals 
[120]. However, a contrasting study identified that the Y30A-Y196A mutant did 
not affect ε-toxin binding or toxicity in ACHN cells or CHO cells expressing the 
MAL protein [73][121]. These data indicate that ε-toxin binds to a secondary 
receptor, which has been suggested to be the MAL protein. Recently a Beta-
octyl glucoside (BOG) molecule was found to bind within domain three of ε-
toxin’s crystal structure [73]. The BOG molecule bound to a different location to 
the HAVCR1 binding site and may be a possible binding site for MAL. Other 
research indicates that several other cell surface proteins are involved in ε-toxin 
intoxication. However, HAVCR1 is the only protein consistently linked to 
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increased expression and ε-toxin susceptibility in other cell lines [73]. This 
therefore suggests that the HAVCR1 protein acts as a receptor or co-receptor 
for ε-toxin but that ε-toxin possesses other binding receptors to establish 
cytotoxicity. 
In 2013, theoretical modelling, using the National Library of medicine 
databases, was employed to investigate other potential ε-toxin binding 
receptors that localise to lipid raft microdomains of endothelial cells and myelin 
[85]. This revealed the MAL protein that fitted these specific criteria and ε-toxin’s 
activity profile. MAL is a highly hydrophobic tetraspan membrane proteolipid 
that resides in epithelial cells, oligodendrocytes, Schwann cells and T 
lymphocytes. In oligodendrocytes and Schwann cells, MAL localises to myelin 
membranes [122]. Functionally, MAL has been implicated in the formation and 
stabilisation of lipid rafts and in the formation of immunological synapses 
[123][124]. The introduction of the mal gene has been reported to transform 
previously insensitive cell lines to cells that demonstrate high sensitivity to ε-
toxin exposure. For example, oligodendrocytes expressing the MAL protein are 
sensitive to ε-toxin while MAL deficient oligodendrocytes are insensitive to ε-
toxin exposure [88]. Similarly, Chinese hamster ovary (CHO) cells are naturally 
resistant to ε-toxin. However, when expressing the MAL protein, these cells 
become immediately sensitive to ε-toxin [85]. Subsequent research also noted 
that CHO cells expressing the rat variant of the MAL protein demonstrated 100x 
greater sensitivity to ε-toxin compared to cells expressing human MAL [85]. 
These data strongly suggest that the MAL protein is necessary and potentially 
involved in ε-toxin’s cell surface binding, oligomerization and pore forming 
capabilities.  
MAL’s structural integrity appears to be critical in establishing protein 
interactions with ε-toxin. In particular, MAL contains two extracellular loops, 
ECL1 and ECL2 that appear to be highly important in facilitating MAL’s binding 
activity with ε-toxin [85][125]. Analysis of the primary structure of ECL2 revealed 
a subtle residue difference between rat and human MAL variants. Human MAL 
contains a glutamate residue at position 114 whereas rat MAL contained a 
phenylalanine residue [85]. Glutamate is a highly polar side chain whereas 
phenylalanine is not. The contrast between these residues may explain the 
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disparity between ε-toxin’s lethality between human and rat species. If MAL is 
the binding receptor for ε-toxin, then ECL2 is likely to play an essential role in ε-
toxin’s pathology and cell surface binding capabilities [85].  
It is possible that the MAL protein is not a direct binding receptor for ε-toxin but 
instead forms part of a co-receptor, receptor complex, or acts as a chaperone 
facilitating the building of a receptor complex without interacting with ε-toxin. 
Studies have noted that the MAL microenvironment is well suited for ε-toxin’s 
activity [85][126][124]. The MAL protein localises in close proximity and high 
concentrations within lipid raft microdomains [85]. This could facilitate ε-toxin 
monomers localising within binding range of each other, thereby favouring direct 
monomer interactions and oligomerisation. Consequently, the current evidence 
strongly suggests that MAL is required for ε-toxin’s binding activity through 
direct or possibly indirect protein interactions.  
ε-toxin’s ability to elicit cytotoxicity in humans is controversial. To date, only two 
cases of ε-toxin producing C. perfringens Type D infections have been 
medically reported in humans [81][127][128]. Both infections were isolated in 
agricultural workers in 1955. However, ε-toxin’s ability to infect some human cell 
lines, including the G-402 human kidney cell line, suggests that ε-toxin 
exposure does pose a genuine risk to human health. In particular, inhalation of 
ε-toxin may result in pulmonary tissue damage and could facilitate ε-toxin’s 
absorption and subsequent dissemination in the bloodstream [81]. Using data 
extrapolation, ε-toxin’s LD50 dose in humans has been estimated at 1 mg/kg via 
the respiratory route [129]. This has been recognised by multiple government 
biodefense agencies that consider ε-toxin to pose a realistic biosecurity threat 
against civilian and livestock populations. Biodefence research has identified 
that aerosolisation would be required to weaponize purified ε-toxin and disperse 
it effectively over large areas [130]. This poses a significant barrier to exploiting 
ε-toxin as a bioterrorism agent, since aerosolisation would require a particle size 
between 1-3 µM in order to sufficiently establish pathogenicity [130]. However, 
despite ε-toxin being recognised to pose a security threat, there are still 
currently no available vaccines that are suitable for use in humans.  
ε-toxin brain exposure in animals causes severe white matter damage in 
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ruminant animals by specifically targeting myelin-forming cells within the CNS to 
initiate cell death [88]. ε-toxin’s demyelination activities in ruminant animals 
have gained attention from researchers who note similar observations in brain 
lesions formed in MS [85]. MS is a degenerative neurological disorder that is 
characterised by the demyelination of nerve cells within the brain and spinal 
cord of humans. The disease is incurable and is one of the most common CNS 
disorders in the world affecting an estimated 2.3 million people globally, with 
varying rates in different countries and populations [131]. The link between MS 
and ε-toxin is not new, with previous researchers recognizing the localisation of 
MS cases in areas of highly concentrated sheep populations [132]. This 
suggested a possible link with a veterinary pathogen. However, the link gained 
renewed attention in 2012, following the isolation of an ε-toxin producing C. 
perfringens Type B strain in a young woman with enhanced brain lesions 
clinical manifestations of MS [75]. This marked the first time in medical history 
that C. perfringens Type B had been isolated in humans. The detection of C. 
perfringens in humans is challenging since the bacterium can exist as an 
endospore that is highly resistant to DNA extraction techniques [75]. However, 
the authors of the study identified that the woman remained positive for C. 
perfringens Type B eight months later [75].  
Mechanistically, ε-toxin’s pathology and demyelination activity in animals fits the 
profile of MS in humans. ε-toxin exposure in animals also results in other MS 
like symptoms including visual impairment, muscular discoordination and 
spastic paralysis [71][116]. Subsequent studies have investigated sera from MS 
patients for immunoreactivity towards ε-toxin. MS sera and cerebrospinal fluid 
(CSF) obtained from sera banks identified that MS patients demonstrated ten 
times greater immunoreactivity to ε-toxin compared to healthy controls [75]. ε-
toxin immunoreactivity was observed in 10% of MS and 1% of healthy controls 
[75]. These low percentages may be explained by the difficulty for humans to 
generate substantial humeral immunity [75]. These results may therefore 
underestimate the true number of MS patients who have been previously 
exposed to ε-toxin. Despite this, collectively the data provides a compelling link 
between ε-toxin exposure and the development of MS. However, further 
research is required to fully confirm whether ε-toxin is responsible for the 
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development of MS in humans.  
Currently there are two challenges facing researchers who are investigating ε-
toxin. The first is lack of a modern toxoid vaccine that can be used to reliably 
prevent ε-toxin disease in domestic livestock populations. As previously 
discussed, current formaldehyde based vaccines are crude and suffer several 
disadvantages that make them unreliable vaccination strategies. There is now 
an emphasis on producing a genetic toxoid vaccine that would provide a more 
reliable method of livestock vaccinations against ε-toxin. The second challenge 
is to elucidate the risk that ε-toxin poses to human health. The recent isolation 
of an ε-toxin producing C. perfringens Type B strain suggests a possible link 
between ε-toxin and the development of MS in humans. This link needs to be 
further investigated to confirm the role of ε-toxin in human health. The research 
conducted in Projects 1 and 2 aim to address both of these challenges by: 
1) Investigating the suitability of new mutagenesis targets for the 
development of a next generation veterinary vaccine against ε-toxin. 
2) Investigating MS sera samples for immunoreactivity towards ε-toxin. 
This data will identify the percentage of MS patients who have been 
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8 PROJECT 1 –Ε-TOXIN’S TOXIN MUTAGENESIS 
8.1 PROJECT OBJECTIVES 
C. perfringens ε-toxin vaccines are available for veterinary use. However, 
current vaccines are based on formaldehyde treated C. perfringens cultures or 
formaldehyde inactivated toxin [133][99]. These imprecise methods suffer from 
batch variability and immunogenicity issues that make these vaccines unreliable 
[141][120]. Consequently, efforts are now being directed towards developing a 
recombinant ε-toxin vaccine based on SDM. Currently, two possible ε-toxin 
binding receptors have been proposed, HAVCR1 and MAL. Research suggests 
that residues present on ε-toxin are important for binding to MDCK cells 
possibly by interacting with a HAVCR1 protein receptor. Mutagenesis of these 
residues abolishes ε-toxin’s toxicity in MDCK cells but does not affect toxicity in 
CHO-hMAL cells. This indicates that there is a secondary receptor for ε-toxin, 
which has been suggested to be MAL. Recently, research identified a BOG 
molecule bound to ε-toxin’s crystal structure [121]. It is possible that this BOG 
binding site is also involved as a binding site for MAL [121].  
In order to construct a safe recombinant vaccine for ε-toxin, toxicity has to be 
abolished in both the MDCK and CHO-hMAL cell lines. Consequently, Project 1 
aims to investigate the importance of ε-toxin’s BOG binding site for cytotoxicity 
against CHO-hMAL cells. To achieve this, the role of seven amino acids within 
the BOG binding site were analysed for their toxicity towards CHO-hMAL cells. 
 The methods to achieve the objectives of Project 1 are as follows: 
1) SDM will be employed to mutate residues within the BOG binding 
domain of ε-toxin. The proposed mutations are: V72F, V72A, F92A, 
T93A, V166A, V166F and A168F.   
2) Plasmid DNA, encoding individual ε-toxin mutants, will be 
transformed and overexpressed into the Rosetta DE3 protein 
expression strain and grown in ZYM-5052 media. 
3) Completed protein expression mutants will be purified and extracted 
 
 
Page | 42 
 
using His and PD10 protein purification columns.  
4) ε-toxin mutant protein concentrations, purity and folding patterns will 
be analysed for each individual mutant.  
5) ε-toxin mutants will be tested for cytotoxicity in the CHO-hMAL cell 
line using the LDH cytotoxicity assay.  
8.1.1 Project Hypothesis 
Site directed mutagenesis of amino acids within the BOG binding domain 
will reduce epsilon toxin cytotoxicity to CHO-hMAL cells by reducing 
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8.2 MATERIALS AND METHODS 
This section contains a detailed account of the different materials and methods 
used to complete all individual experiments undertaken in Project 1.  
8.2.1 Plasmid  
The pET-26b(+) vector containing the WT ε-toxin gene was generated in 
Professor R. Titball’s laboratory by M. Bokori-Brown (unpublished). The 
pET26b(+) plasmid was the only vector used for the ε-toxin mutagenesis study 
(Addgene plasmid # 69862-3). 
8.2.2 Oligonucleotide Primer Design 
Mutagenic primers for ε-toxin were designed using the QuikChange Primer 
Design Program. The pET26b-etxD plasmid FASTA sequence was obtained 
and nucleotide base changes encoding the required amino acid substitution 
were selected to produce reverse primers. Reverse primers were reverse 
complemented to produce the forward primers. Oligonucleotide primers used in 
Project 1 can be seen in Appendix B. 
8.2.3 Site Directed Mutagenesis – Mutant Strand Synthesis Reaction 
The primers encoding the ε-toxin mutations were incorporated into the pET26b-
etxD plasmid by SDM. The mutagenesis reaction was prepared by mixing the 
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Reagent Volume (µl) 
10X Buffer 5 
Plasmid (5 ng/µl) 5 
Primer One (100 ng/µl) 1.25 
Primer Two (100 ng/µl) 1.25 
dNTPs 1 
QuikSolution Change 1.5 
H2O 34 
QuikChange Enzyme 1 
Table 8-1 - SDM Reaction Constituents 
SDM was completed using the QuikChange Lightning Mutagenesis Kit 
(Promega) following the corresponding protocol [134]. Briefly, SDM constituents 
were cooled on ice and mixed together. In all cases the QuikChange enzyme 
was the last addition to the reaction mixture.  
8.2.4 Site Directed Mutagenesis – Mutant Strand DNA Amplification 
Polymerase chain reaction (PCR) was used to amplify the mutant plasmid DNA. 
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Reaction Step Temperature (°c) Time (sec) Cycles 
Initial Denaturation 95 120  
Denaturation 95 20  
Primer Annealing 60 10 17 
Primer Extension 68 210  
Final Extension 68 300  
Final Hold 10 ∞  
Table 8-2 - PCR Conditions.  
Mutant plasmid DNA samples were amplified by PCR using a C1000™ Thermo 
Cycler (BioRad) following the QuikChange Lightning Mutagenesis Kit Protocol 
[134]. Briefly, DNA samples were denatured at 95°C, primers were annealed to 
the plasmid template at 60°C and primer extension was completed at 68°C. 
Completed PCR samples were held at 10°C.  
8.2.5 Heat Shock Bacterial Transformation – XL10-Gold Ultra-competent 
E.coli 
Mutant plasmid DNA was transformed into XL10-Gold Ultra-competent E.coli by 
heat shock following the QuikChange Lightning Mutagenesis Kit Protocol [134]. 
Briefly, mutant plasmid DNA was mixed with 2 µl of the DpnI enzyme and 
incubated at 37°C for five minutes. 45 µl aliquots of XL10-Gold E.coli cells were 
gently thawed on ice, mixed with 2 µl of β-mercaptoethanol and incubated on 
ice for two minutes. 2 µl of each mutant plasmid DNA sample was added to a 
separate XL10-Gold E.coli aliquot. The DNA samples were incubated on ice for 
30 minutes. Samples were heat shocked for 30 seconds at 42°C and 
immediately returned to ice for two minutes.  
Each sample was inoculated with 100 µl of super optimal broth with catabolite 
repression (SOC) medium and incubated for one hour in an orbital shaking 
incubator at 37°C, 250 rpm. 100% of each sample was plated on lysogeny broth 
(LB) agar containing kanamycin (50 µg/ml). Plated samples were incubated 
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overnight at 37°C and 5% CO2. 
8.2.6 MINI Prep (DNA Purification) 
For each mutant sample, three transformed XL10-Gold E.coli colonies were 
inoculated into 5 ml of LB broth containing Kanamycin (50 mg/ml). Bacterial 
samples were grown overnight in a shaking incubator set at 37°C, 250 rpm 
before centrifugation at 10,000g for 20 minutes. The Thermo scientific MINI-
prep Protocol A was then followed [135]. Briefly, bacterial cells were re-
suspended, lysed, neutralised and centrifuged. The supernatant was extracted 
and the samples washed to purify DNA. DNA was eluted in 30 µl of sterile 
water. DNA concentrations were quantified using a Thermo Scientific NanoDrop 
ND-2000C machine. DNA samples were stored at -20°C. 
8.2.7 DNA Sequencing and Analysis 
Successful mutagenesis was confirmed by DNA sequencing following the 
Eurofins DNA submission guide. Briefly, plasmid DNA samples were diluted 
with deionised water to a concentration between 50-100 ng/µL [136]. 15 µL of 
each mutant DNA sample was pipetted aseptically to separate 1.5 mL micro-
centrifuge tubes fitted with safe-lock screw cap seals to prevent evaporation. 
DNA samples were analysed using Value Read (Eurofins Genomics). Two DNA 
aliquots were submitted for each mutagenesis sample. One aliquot was 
analysed using the T7 forward primer, the other was analysed using the T7 
Terminal backwards primer.  
Sequencing data was analysed using the BioEdit program and compared to a 
reference plasmid containing the WT ε-toxin gene [137]. T7 Terminal genetic 
sequences were reverse complemented before sequences were compared 
using the ClustalW multiple alignment tool. Non-conserved sequences were 
deleted and sequences checked for successful SDM within the target site.   
8.2.8 Bacterial Amplification – E.coli Rosetta DE3 
Confirmed SDM mutants were transformed into the Rosetta DE3 E.coli 
expression strain by heat shock [138]. Briefly, 10 µl aliquots of Rosetta DE3 
were prepared in pre-chilled 1.5 ml Eppendorf tubes for each sample. For each 
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mutant DNA sample, 10 ng/µl stocks were produced through dilution in 
deionised water. 1 µL of diluted plasmid DNA was added to a Rosetta DE3 
E.coli aliquot and incubated on ice for five minutes. Transformation samples 
were heat shocked at 42°C for 30 seconds before being immediately returned 
to ice for two minutes.  
Transformation samples were inoculated with 90 µl of SOC medium and 
incubated for one hour in an orbital shaking incubator set at 37°C, 200 rpm. 
100% of the transformation sample was plated on LB agar containing 
kanamycin (50 µg/ml) and chloramphenicol (34 µg/ml). Plated samples were 
incubated overnight at 37°C, 5% CO2. 
8.2.9 ZYM-5052 Media Preparation 
ε-toxin mutant protein expression was maximised using ZYM-5052 autoinducer 
media. ZYM-5052 media was prepared based on an adaptation of the protocol 
by Studier et al. [139]. Briefly, 10g of tryptone and 5g of yeast extract were 
added to 960 ml of deionised water. Following sterilisation by autoclaving, 20 ml 
of 50x M-solution, 20 ml of 50x “5052” solution, 1 ml of 2 M MgSO4, 200 µl of 
1000X trace metals were added to the solution. ZYM-5052 media was stored in 
a ventilated cold room at 5°C.  
8.2.10 Protein Expression in ZYM-5052 Media 
ZYM-5052 aliquots were prepared according to the number of transformation 
samples. Kanamycin (50 µg/ml) and Chloramphenicol (34 µg/ml) were added to 
the ZYM-5052 aliquot in a 1/1000 dilution. 100 ml of ZYM-5052 solution was used 
for each protein expression sample. 1/10 of the total flask volume was filled with 
ZYM-5052 media to ensure oxygenic conditions. 100 µl of each transformation 
sample was pipetted aseptically into the ZYM-5052 media. Cells were grown for 
three hours at 37°C at 300 rpm before further incubation for 24 hours at 20°C at 
300 rpm.  
Following incubation, cell density was measured using an Ultrospec-10 
spectrophotometer (GE Healthcare). Briefly, 100 µl of each sample was mixed 
with 900 µl of ZYM-5052 media. Experimental optical density (OD) readings 
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were compared to a blank that contained 1000 µl of ZYM-5052.  
Nalgene® 500 ml centrifuge bottles were used for centrifuging each sample. 
The weight of each bottle was measured and, using a class two safety cabinet, 
the bacterial solution poured into individual Nalgene® bottles before 
establishing the solution weight. ZYM-5052 media was added to samples to 
balance the weight (±1g) for centrifugation completed for ten minutes at 
10,000g, 4°C. Using a class two safety cabinet, the supernatants were removed 
and the pellets allowed to dry. Pellet weights were calculated by subtracting the 
known weight of the bottle. Bacterial pellets were stored in the Nalgene® bottles 
at -80°C. 
8.2.11 Protein Purification Preparation 
Bacterial pellets were mixed with lysis agents to prepare them for protein 
purification (Table 8-3). The solution was carefully pipetted up and down to 
detach and suspend bacterial cells into the solution. The solution was incubated 
on a rocker for twenty minutes at room temperature and centrifuged at 16,000g 
for twenty minutes at 4°C.  
Reagent Volume (µl) 
Bugbuster 5 
R-Lysozyme 5 
Benzonase Nuclease 1.25 
Table 8-3 - Protein Purification Bacterial Lysis Reagents 
8.2.12 Protein Purification – HisTrap HP Buffers 
A HisTrap HP Column was used to purify the mutant ε-toxin protein. The 
HisTrap HP column buffers for protein purification were produced in the 
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Buffer Type Imidazole (µl) Phosphate 
Buffer (µl) 
H2O (ml) 
Binding Buffer 100 1250 8.65 
Wash Buffer 300 1250 8.45 
Elution Buffer 750 375 1.875 
Table 8-4 - Protein Purification HisTrap HP Column Buffers 
8.2.13 Protein Purification – HisTrap HP Column 
HisTrap HP protein purification was completed following the GE Healthcare 
protocol [140]. Briefly, the HisTrap HP column tip was removed and excess 
liquid drained. The column was loaded onto a stand and equilibrated with 10 ml 
of binding buffer. The prepared sample was added and allowed to pass through 
the column. The column was washed using 10 ml of prepared wash buffer. 
Finally, the protein was eluted in 3 ml of elution buffer. 
8.2.14 Protein Purification – PD-10 Desalting Column 
PD-10 Desalting protein purification was completed following the GE Healthcare 
gravity protocol [141]. Briefly, the PD-10 column tip was removed, and excess 
liquid drained. The column was equilibrated with 25 ml of phosphate buffer 
saline (PBS). Following equilibration, 2.5 ml of the protein sample was added. 
Finally, the protein was eluted in 3.5 ml of PBS buffer, transferred into 500 µl 
aliquots and stored at -20°C.  
8.2.15 Protein Analysis 
 NanoDrop 8.2.15.1
ε-toxin mutant concentrations were quantified using a Thermo Scientific 
NanoDrop ND-2000C machine. Briefly, the NanoDrop machine was calibrated 
using 2 µl of deionised H2O. Using the A280 program, the NanoDrop machine 
was blanked with PBS before 2 µl of experimental sample was analysed for 
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protein concentration. 
 SDS-PAGE Analysis 8.2.15.2
The molecular weight and purity of ε-toxin mutants were analysed by Sodium 
Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS–PAGE). ε-toxin 
mutants were boiled for ten minutes on a heat block, pulsed for two minutes in a 
micro-centrifuge at full speed and mixed with 10 µL of 4x LDS loading buffer 
solution. A precast twelve well NU-PAGE 4-12% Bis-Tris gel (ThermoFisher 
Scientific) was washed with deionised water before loading into the SDS-PAGE 
chamber. Using 1x MES solution, the central chamber was fully filled with outer 
chambers being half filled.  
5 µl of Perfect Protein Marker 10-225kD ladder (Merck) was loaded onto the 
NU-PAGE gel alongside 10 µl of each protein sample. The gel electrophoresis 
was run for 45 minutes at 180V, 400mA. Following electrophoresis, the gel was 
removed and washed with deionised water. Gel staining was completed by 
submerging the gel in SimplyBlue SafeStain (ThermoFisher Scientific) and 
microwaving for 30 seconds. The gel was incubated on a rocker at room 
temperature for one hour. The SimplyBlue SafeStain was removed and the gel 
submerged in deionised water. The gel was incubated overnight at room 
temperature on a rocker. Imaging was completed using the ChemiDoc™ XRS 
system Epiwhite mode and ImageLab™ software (BioRad).  
 Mass Spectrometry 8.2.15.3
ε-toxin mutagenesis and sample purity was analysed using Liquid 
Chromatography Mass Spectrometry (LCMS). One aliquot for each ε-toxin 
mutant was standardised to a concentration of 1 mg/ml. From this 50 µl (50 µg) 
samples were pipetted aseptically into 2 ml screw cap tubes with an O-ring to 
prevent sample loss by evaporation. Samples were sent on dry ice to the 
University of Bristol Proteomics Facility for LCMS analysis. Each sample was 
trypsin digested before separation by high performance liquid chromatography 
and spectroscopy analysis. Protein samples were ionised and the protein mass 
identified through mass spectrometry. Digested peptides for each mutagenesis 
sample were compared and scored according to their spectral match with 
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digested Etx-YY peptides. Peptide spectra match (PSM) scores were analysed 
between cut-off percentage confidence limits (identified at >1% False Discovery 
Rate, <5% False Discovery rate). This ensured a 95% confidence level in the 
mass spectrometry peptide analysis. For non-contaminated samples, the total 
PSM score for every peptide was calculated. In contaminated samples, the 
peptides were screened for the presence of the expected mutation and 
screened again for the contaminant. The PSMs for each peptide matching with 
the expected mutant and contaminant were calculated.  
8.2.16 CHO-hMAL Resuscitation 
Frozen 1 ml CHO-hMAL cell samples, stored in cryovials at -80˚C, were 
resuscitated in a water bath at 37˚C. Cryovials were thawed by gentle agitation 
at 37˚C until no ice crystals were present in the sample. The O-ring and cryovial 
cap were kept out of the water to reduce the risk of contamination. Cell thawing 
was completed quickly to reduce dimethyl sulfoxide (DMSO) toxicity to CHO-
hMAL cells. 
Once fully thawed, the cryovials were decontaminated using 70% ethanol. 
Working in a class two biological safety cabinet, the 1 ml CHO-hMAL sample 
was transferred into a 15 ml Falcon tube. 10 ml of pre-warmed Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% Fetal Bovine Serum (FBS) 
was added to the CHO-hMAL cell suspension in the 15 ml Falcon tube. The 
CHO-hMAL cell solution was transferred to a T25 flask and incubated overnight 
at 37˚C, 5% CO2. The cell medium was replaced with fresh DMEM 10% FBS 
the following day to remove all DMSO. CHO-hMAL cells were grown to 90% 
confluency in the T25 before transferral to a T75 flask. 
8.2.17 CHO-hMAL Cell Culturing (T25 Flask) 
CHO-hMAL cells were viewed for confluency using an inverted light 
microscope. T25 flasks <90% confluent were returned for incubation at 37˚C, 
5% CO2. 
T25 flasks that demonstrated ~90% confluency were prepared for cell splitting. 
Working in a class two biological safety cabinet, cell media was removed and 
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the flask was washed twice with 5 ml of PBS. To detach the CHO-hMAL cells, 1 
ml of heat inactivated trypsin was added and the flask incubated at 37˚C, 5% 
CO2 for two minutes. After detachment, cells were diluted in 4 ml of DMEM and 
mixed thoroughly to separate CHO-hMAL aggregates. The full contents were 
transferred to a T75 flask along with 10 ml of DMEM.  T75 flasks were 
incubated at 37˚C, 5% CO2 until 90% confluent. 
8.2.18 CHO-hMAL Cell Culturing (T75 Flask) 
CHO-hMAL cells were viewed for confluency under an inverted light 
microscope. T75 flasks <90% confluent were returned for incubation at 37˚C, 
5% CO2. 
T75 flasks that demonstrated ~90% confluency were prepared for culturing. 
Working in a class two biological safety cabinet cell media was removed and 
the flask was washed twice with 10 ml of PBS. To detach the CHO-hMAL cells 
from the flask, 3 ml of heat inactivated trypsin was added and the flask 
incubated at 37˚C, 5% CO2 for ten minutes. After detachment, the cells were 
diluted in 7 ml of DMEM and mixed thoroughly to separate CHO-hMAL 
aggregates. The full contents were transferred to a 15 ml Falcon tube. Using 
this cell solution, T75 flasks were set up for future experiments. 3 ml of cell 
solution was added to T75 flasks for next day experiments, 1.5 ml used for mid-
week experiments and 0.5 ml for end of week experiments. These cell solutions 
were filled to 15 ml with DMEM 10% FBS. Completed flasks were incubated at 
37˚C, 5% CO2 until confluency reached 90%. 
8.2.19 CHO-hMAL Cell Culturing - Assay Preparation 
CHO-hMAL cells were viewed for confluency using an inverted light 
microscope. T75 flasks <90% confluent were returned for incubation at 37˚C, 
5% CO2 and checked. 
T75 flasks that demonstrated ~90% confluency were prepared for culturing. 
Working in a class two biological safety cabinet, cell media was removed and 
the T75 flask was washed twice with 10 ml of PBS. To detach the CHO-hMAL 
cells, 3 ml of heat inactivated trypsin was added and the flask incubated at 
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37˚C, 5% CO2 for ten minutes. Detached cells were diluted in 7 ml of DMEM 
and mixed thoroughly to separate CHO-hMAL aggregates. The full contents 
were transferred to a 15 ml Falcon tube. In a 1.5 ml Eppendorf, a 1/10 cell 
dilution was produced by mixing 800 µl of DMEM, 100 µl of CHO-hMAL cell 
suspension and 100 µl of 0.4% Tryphan Blue (Sigma-Aldrich). 20 µl of the 1/10 
cell dilution was pipetted onto a haemocytometer for cell counting and viewed 
using an inverted light microscope. Cells stained by the Tryphan Blue were 
excluded from the cell count.  
Cell suspension and DMEM volumes required to produce the CHO-hMAL 
seeding density of 3x106 cells/ml was identified using the haemocytometer cell 
count. A 10 ml aliquot of CHO-hMAL cell solution at the seeding density of 
0.3x106 cells/ml was produced in a 15 ml Falcon tube. Using a pipette, 100 µL 
of CHO-hMAL cells at seeding density were pipetted into wells on a 96 well 
plate. Completed 96-well plates were incubated overnight at 37°C, 5% CO2. 96-
well plates were inspected before beginning experimentation.  
8.2.20 Cytotoxicity Assay - ε-toxin Mutants 
Following the manufacturer’s instructions, a CytoTox96® Non-Radioactive LDH 
Cytotoxicity Assay (Promega) was used, to analyse ε-toxin mutant cytotoxicity 
against CHO-hMAL cells. Briefly, WT ε-toxin concentration (mg/ml) was 
identified using a NanoDrop 1000 (BioRad) and converted to molar 
concentration using the equation in Equation 1. 
𝐶𝑜𝑛𝑣𝑒𝑟𝑡
𝑚𝑔
𝑚𝐿 𝑡𝑜 𝑢𝑀 =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑊𝑒𝑖𝑔ℎ𝑡  𝑥10
! 
Equation 1 - Concentration conversion (mg/ml to molar concentration). 
ε-toxin mutants were diluted to a starting concentration of 0.2 mg/ml using PBS. 
10 µl of the inactivated ε-toxin was pipetted into a 1.5 ml Eppendorf and mixed 
with 10 µl of 4xLDS buffer for SDS PAGE analysis (Section 8.2.15.2). A 1/100 
volume of 0.2 mg/ml trypsin solution was used to activate ε-toxin. This solution 
was incubated at room temperature for 30 minutes to ensure complete toxin 
activation. 10 µl of trypsin-activated ε-toxin was pipetted into a 1.5 ml Eppendorf 
and mixed with 10 µl of 4xLDS Buffer for SDS PAGE analysis (Section 
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8.2.15.2). Using a 96-well V-bottomed plate, activated ε-toxin mutants were 
diluted in PBS through a two-fold dilution.  
Using a previously seeded 96 well plate, old cell media was replaced with 80 µl 
of pre-warmed DMEM. 20 µl of each two-fold dilution containing activated ε-
toxin was transferred to respective wells on the seeded plate. 20 µl of the 
control samples were each added to three seeded control wells (Table 8-5). The 
96-well plate was incubated at 37°C, 5% CO2 for three hours. Following 
incubation, 50 µl of cell culture medium was transferred from each well to a 
fresh 96-well plate and mixed with 50 µL of reconstitution substrate mix. 
Following a 30 minute incubation in the dark at room temperature, the wells 
were mixed with 50 µl of stop solution and cytotoxicity measured at 490 nm 
using a microplate reader (BioRad). The mean PBS negative control was 
subtracted from all experimental values and data analysed for neutralisation 
activity and the cytotoxic 50% dose calculated using non-linear regression 
analysis. The cytotoxic 50% dose was calculated using non-linear regression 
analysis. 
WT ε-toxin Cytotoxicity 
LDH Assay Controls 
Control Type 
PBS Negative 
0.1X Triton X Positive 
Table 8-5 - Experimental controls employed for the LDH Assay 
investigating Wild Type ε-toxin Cytotoxicity to CHO-hMAL cells. 
8.2.21 Cytotoxicity Assay - ε-toxin Mutant CT50  Calculation 
Following the LDH Cytotoxicity Assay (described in 8.2.20), the CT50 dose of 
the ε-toxin site directed mutants was compared to the Etx-YY background CT50.  
Using Graphpad Prism 7, the CT50 values of each of the SDM samples was 
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8.3 RESULTS  
This section describes the results obtained from all experiments completed in 
Project 1. 
8.3.1 Amino Acid Mutagenesis Selection 
The work in Project 1 aims to investigate the mutagenesis of seven critical 
residues within the BOG binding domain and their effects towards ε-toxin’s 
toxicity against CHO-hMAL cells. The introduced mutations were V72A, V72F, 
F92A, T93A, V166A, V166F and A168F. These residues were chosen since 
they were previously shown to bind to the BOG ligand (Figure 8-1) [121]. 
Mutagenesis was completed using a variant form of ε-toxin containing the 
Y43A-Y209A mutations within the HAVCR1 binding domain (Figure 8-1). This 
form of ε-toxin, referred to as Etx-YY, was used as the DNA template for 
mutagenesis and retained full cytotoxic activity against CHO cells expressing 








Figure 8-1 - The three domain protein crystal structure of the Clostridium 
perfringens epsilon prototoxin [121]. The figure illustrates the putative 
membrane insertion loop of domain II in red. (A) Illustrates previously 
mutated residues in domain I. Of these the Y43A and Y209A were shown 
to markedly reduce binding to MDCK cells. (B) Illustrates residues within 
domain III involved in the co-ordination of a single BOG molecule. Amino 
acid numbering excludes the 13 N-terminal peptide sequence.  
8.3.2 Bacterial Transformation – DNA Sequencing 
Following bacterial transformation, successful mutagenesis was confirmed by 
nucleotide sequencing. The ε-toxin mutant plasmids were subsequently referred 
to by their respective mutations (V72A, V72F, F92A, T93A, V166A, V166F and 









Green   =  Etx-YY mutations 
Yellow   =  V72A and V72F mutations 
Red    =  F92A mutation 
Turquoise   =  T93A mutation 
Lilac    = V166A and V166F mutations 
Blue    =  A168F mutation 
Figure 8-2 - DNA and amino acid sequences of V72A, V72F, F92A, T93A, 
V166A, V166F and A168F ε-toxin mutants introduced into the Etx-YY 
background. Individual V72A, V72F, F92A, T93A, V166A, V166F and A168F 
amino acid substitutions introduced into the Etx-YY background by SDM 
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were confirmed by nucleotide sequencing the mutated etx gene. 
Completed nucleotide sequences for all seven mutagenesis samples as 
presented in Appendix A. 
8.3.3 Protein Purification – Protein Concentrations 
ε-toxin mutant concentrations ranged from 1.29 mg/ml to 2.61 mg/ml with a 
mean concentration of 1.86 mg/ml (Figure 8-3). All seven mutants 
demonstrated lower protein concentrations compared to the Etx-YY 
concentration of 2.82 mg/ml.  
 
Figure 8-3 - Concentrations of ε-toxin mutants. Mutant proteins were 
expressed in E.coli, purified using nickel affinity and PD10 column 
chromatography and concentrations measured using a NanoDrop 
spectrophotometer at 280nm. Results shown were taken from a single 
measurement expressed as mg/ml.  
8.3.4 Protein Purification – SDS PAGE protein purity analysis 
ε-toxin mutant purity was analysed by SDS-PAGE, which revealed that a single 
protein band was present for each of the ε-toxin mutant samples (Figure 8-4). 
The protein bands of all seven mutants correspond to the 35 kDa marker on the 























































Figure 8-4 - SDS-PAGE analysis of ε-toxin mutants with SimplyBlue gel 
staining. Mutant proteins were subject to electrophoresis on a 4-12%SDS-
PAGE following boiling and centrifugation treatment. Imaging was 
completed using Chemidoc™ Epiwhite mode. (A) shows V72A, T93A, 
V166F and A168F mutant samples compared to a 10-225 kDa protein 
ladder. (B) shows V72F, F92A and V166A mutant samples compared to a 
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8.3.5 LDH Assay – ε-toxin Mutant CHO-hMAL Cytotoxicity  
ε-toxin mutant cytotoxicity against CHO-hMAL cells was investigated using an 
LDH assay through a two-fold dilution. OD readings of LDH release correlate to 
the cytotoxicity profile for each ε-toxin mutant and were compared to the Etx-YY 
background (Figure 8-5). V72A and T93A mutants retained full CHO-hMAL 
cytotoxicity for five dilutions and exhibited similar cytotoxicity profiles to the Etx-
YY background. The F92A and V166A mutants demonstrated reduced CHO-
hMAL cytotoxicity compared to the Etx-YY background but retained cytotoxicity 
at higher concentrations between 0.5 and 1 mg/ml. The V72F, V166F and 
A168F mutants abolished CHO-hMAL cytotoxicity at all concentration ranges 









































































































Figure 8-5 - Cytotoxicity analysis of ε-toxin mutants compared to Etx-YY. 
Mutant proteins and Etx-YY were diluted through a two-fold dilution 
starting at a concentration of 0.2 mg/ml. The figure illustrates the optical 
density measuring mean LDH release from CHO-hMAL cells incubated 
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measured at OD490nm. The error bars represent the standard error of the 
mean. 
8.3.6 LDH Assay - ε-toxin Mutant CHO-hMAL CT50 
The ε-toxin mutant CT50 concentrations against CHO-hMAL cells were 
determined using the LDH assay data in Figure 8-5 and are listed in Table 8-6 
along with their respective 95% confidence intervals. 




V72A 5.9x10-3 ±2.1x10-3 
V72F >0.2 N/A 
F92A 18.6 x10-3 ±6.7x10-3 
T93A 6.3 x10-3 ±2.3x10-3 
V166A 44.5 x10-3 ±15.9x10-3 
V166F >0.2 N/A 
A168F >0.2 N/A 
Etx-YY 2.9x10-3 ±1.0 x10-3	
Table 8-6 - ε-toxin mutant CT50 concentration against CHO-hMAL cells 
Figure 8-6 illustrates the fold difference of the ε-toxin mutant CT50 
concentrations compared to the Etx-YY CT50. The V72A and T93A mutants 
exhibited a two-fold CT50 reduction in CHO-hMAL cytotoxicity. The F92A and 
V166A mutants showed a 6.4 and 15.3 fold CT50 reduction against CHO-hMAL 
cells respectively.  The V72F, V166F and A168F mutants abolished cytotoxicity 
at all assay concentrations up to 0.2 mg/ml (Figure 8-5). Consequently, the 
CT50 concentrations for these samples exceed a 68.8 fold attenuation compared 
to the Etx-YY background.  
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Figure 8-6 - Comparing the CT50 concentration differences between Etx-YY 
and the individual ε-toxin mutants.  The fold difference was calculated by 
divided individual mutant CT50 concentrations by the Etx-YY CT50 
concentration. Results shown were taken from two replicates. The error 
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8.3.7 Protein Purification – Mass Spectrometry analysis 
LCMS was employed to confirm successful ε-toxin mutagenesis and sample 
purity (Figure 8-7). The V72F, F92A, T93A and A168F samples demonstrated 
zero PSMs for the Etx-YY background and PSM scores of 61, 836, 655 and 871 
for their respective mutations. These data confirmed the successful 
mutagenesis and purity of these samples.  
The V72A and V166A samples demonstrated respective PSM scores of ten and 
three for the Etx-YY background and scores of 112 and 36 for their respective 
mutations. These data confirmed the successful mutagenesis of these samples 
but revealed that they were contaminated with the Etx-YY background.  
The V166F sample demonstrated zero PSMs for the Etx-YY background and 
PSM scores of 29 for the V166F mutation and two for the A168F mutation. 
These data confirmed successful V166F mutagenesis but revealed that the 
sample was contaminated with the A168F sample.  
 
V72A V72F F92A 
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T93A V166A V166F 
   
A168F 
 
Figure 8-7 - Mass spectrometry analysis of ε-toxin mutants. Results show 
the total PSM number for proteins present in each ε-toxin mutant sample. 
The PSM number equates to the total number of peptides matched to each 
protein. The mass spectrometry analysis was completed by the University 
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8.3.8 Mass Spectrometry – V72A and V166A Contamination Analysis 
Etx-YY contamination was analysed by investigating if the Etx-YY contaminant 
present in the V72A and V166A samples was sufficiently concentrated to 
interfere with cytotoxicity data (Section-8.3.5). To do this, the Etx-YY 
concentration present in the 0.2 mg/ml V72A and V166A cytotoxicity assay 
samples was estimated using the percentage Etx-YY PSM scores in Table 8-7. 
The number of two fold dilutions required to dilute the Etx-YY contaminant 
concentration to its CT50 concentration was then compared to the number of 
two fold dilutions required to obtain the CT50 of the contaminated samples 





Etx-YY Concentration in 0.2 
mg/ml Cytotoxicity Assay 
V72A 8.9% 17.8x10-3 mg/ml 
V166A 7.6% 15.2x10-3 mg/ml. 
Table 8-7 - Illustrates the relative percentage Etx-YY PSM scores and 
concentrations present in the 0.2 mg/ml cytotoxicity assay starting 








2! = 𝐸𝑡𝑥𝑌𝑌 𝐶𝑇50 




Equation 2 - Number of two fold dilutions required to dilute Etx-YY 




CT50 – Two 
Fold Dilutions 
Etx-YY Contaminant CT50 Two 
Fold Dilutions in 0.2 mg/ml 
Cytotoxicity Assay 
V72A 6.11 2.62 
V166A 2.17 2.29 
Table 8-8 - Illustrates the number of two fold dilutions required to obtain 
the CT50 concentration of the V72A and V166A samples and the Etx-YY 
contamination present in the 0.2 mg/ml starting concentration of the V72A 
and V166A samples.  
  
Therefore for V72A… 
0.0178




𝐿𝑜𝑔(2) = 2.62 
   Therefore for V166A… 
0.0152




𝐿𝑜𝑔(2) = 2.29 
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V72A and V166A PSM analysis revealed that 8.9% and 7.6% of the sample 
composed of the Etx-YY contaminant respectively. This equates to a respective 
17.8x10-3 mg/ml and 15.2x10-3 mg/ml Etx-YY concentration present in the 0.2 
mg/ml starting concentration of the V72A and V166A cytotoxicity assay samples 
(Table 8-7). Dilution analysis using Equation 2 revealed that 2.62 and 2.29 two-
fold dilutions were required to dilute the V72A and V166A Etx-YY contamination 
to the Etx-YY CT50 concentration respectively. Table 8-8 shows that the number 
of two-fold dilations required to obtain the V166A CT50 compares closely to the 
number of dilutions required to obtain the Etx-YY contaminant CT50 
concentration. However, the number of two-fold dilations required to obtain the 
V72A CT50 does not compare closely to the number of dilutions required to 
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8.4 DISCUSSION 
NanoDrop protein analysis revealed that the purified ε-toxin mutant 
concentrations were greater than the WT ε-toxin CT50 (Section 9.3.1). ε-toxin 
mutant concentrations were generally consistent suggesting that the HisTrap 
HP and PD-10 were reliable protein purification methods (Figure 8-3). However, 
protein concentrations were obtained from single NanoDrop measurements 
only. Consequently, there is a risk that small molecular sample contaminants, 
including nucleic acids and lipoproteins, could have influenced the A280 
absorption readings [142]. This would culminate in inaccurate protein 
concentration results. ε-toxin mutant concentrations shown in Figure 8-3 could 
be validated using a secondary protein quantification technique, such as the 
Bradford, Lowry, or BCA assays. With these methods, ε-toxin mutant 
concentrations would be analysed spectrophotometrically by a colour change. 
Absorption readings could then be compared to a known protein standard such 
as the Etx-YY protein background or bovine serum albumin [143]. These 
methods are unaffected by small sample contaminants and could therefore 
quantify ε-toxin mutant concentrations more accurately compared to a 
NanoDrop spectrophotometer. However, all seven ε-toxin mutants contain a 
high cysteine content that may produce artificially high results using the BCA 
assay [142]. Consequently, more accurate protein concentration results may be 
obtained using the Lowry or Bradford assays instead. 
SDS-PAGE analysis revealed that the protein bands of all seven ε-toxin 
mutants correlated closely to the 33 kDa size of WT ε-toxin. This suggested that 
these samples contained the desired ε-toxin mutants [73] (Figure 8-4). 
Contaminant bands were not visible, therefore if any sample contamination 
existed it would be at very low concentrations. However, the SDS-PAGE 
method cannot distinguish molecular differences between these proteins and 
therefore could not confirm the purity or successful mutagenesis of these 
samples. To further investigate this, samples were analysed by mass 
spectrometry. Mass spectrometry analysis confirmed the purity and successful 
mutagenesis of the V72F, F92A, T93A, and A168F samples (Figure 8-7). 
However, the V72A and V166A mass spectrometry analysis revealed that these 
samples were contaminated with Etx-YY protein. The Etx-YY contaminant 
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accounted respectively for 8.9% and 7.6% of the total V72A and V166A PSM 
scores suggesting that the contamination in both samples was considerable. 
The Etx-YY contamination could have been introduced through two possible 
means, described in 1) and 2) below. In both possibilities, bacteria encoding the 
Etx-YY contaminant would have grown during protein expression and would not 
be separated from the desired V72A and V166A mutants during protein 
purification. This would result in a contaminated final elution that could have 
affected the cytotoxicity profiles of the V72A and V166A samples.  
1) The Etx-YY contamination could have been introduced into the 
V72A and V166A samples through human error. This would have 
most likely occurred during the bacterial transformation or protein 
purification of these samples. 
2) The V72A and V166A mutants may have reverted back to the Etx-
YY background as a result of back mutations. Theoretically this 
could have occurred at any point following bacterial transformation. 
Reversion mutations are unlikely to occur unless there is an 
evolutionary driver favouring the reverted protein. The V72A and 
V166A mutations are not known to be evolutionarily detrimental to 
transformed bacteria. Consequently, it is considered unlikely that the 
Etx-YY contamination was introduced through a reversion mutation 
event.  
Mass spectrometry also confirmed that the V166F mutant was contaminated 
with A168F (Figure 8-7). The A168F contaminant accounted for 6.7% of the 
total V166F PSM score suggesting that the contamination was substantial. The 
contamination was most likely introduced as a result of human error since 
protein expression and purification experiments were completed separately 
under aseptic conditions.  
The cytotoxicity analysis performed in Figure 8-5 and Figure 8-6 was completed 
using only two replicates for each mutagenesis sample. Consequently, the data 
can only provide the spread of the results without a reliable indication of a 
statistical mean value. Despite the small spread of the results, the reliability of 
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the cytotoxicity analysis in Figure 8-5 and Figure 8-6 would be improved with 
more replicates.  
The purity of the V72F, A168F, F92A and T93A samples confirmed that their 
cytotoxicity profiles were representative of their mutations. The cytotoxicity data 
revealed that the V72F and A168F samples were non-toxic to CHO-hMAL cells 
at all concentrations used in the cytotoxicity assay (Figure 8-5). The abolished 
cytotoxicity of the V72F and A168F mutants suggests that these residues are 
critical for ε-toxin cytotoxicity by potentially altering the structural integrity of the 
BOG binding site. The F92A and T93A mutants also demonstrated reduced 
CHO-hMAL cytotoxicity compared to the Etx-YY protein but retained cytotoxicity 
at higher concentrations (Figure 8-5). This suggests that the F92 and T93 
residues are involved but inessential for ε-toxin cytotoxicity. One possible 
explanation is that the F92A and T93A mutations fail to introduce a significant 
structural change to abolish ε-toxin’s cytotoxicity, therefore enabling ε-toxin to 
retain its cytotoxic properties. This could be because the BOG binding site 
remains functional but with reduced binding efficiency, which could explain why 
both mutants retain some cytotoxicity. Consequently, the cytotoxicity data from 
the V72F, A158F, F92A and T93A samples suggest that the BOG binding site is 
potentially responsible for ε-toxin’s cytotoxicity towards CHO-hMAL cells, 
possibly mediated by binding to the MAL protein as a receptor. 
The V166F sample also demonstrated abolished CHO-hMAL cytotoxicity, but 
was contaminated with the non-cytotoxic A168F mutant (Figure 8-7). A168F’s 
non-cytotoxic properties suggest that it was unlikely to have affected the V166F 
cytotoxicity results. Consequently, the V166F cytotoxicity data is likely to be 
representative of a pure V166F sample, however, this may not be true for 
concentrations beyond the range used in the assay. The cytotoxicity results 
therefore suggest that the V166F mutation inhibits ε-toxin cytotoxicity, 
potentially by altering the structural integrity of the BOG binding site (Figure 
8-5). However, future experiments are required to re-purify and test the V166F 
sample to confirm its effect on ε-toxin cytotoxicity.  
The V166A sample also demonstrated reduced CHO-hMAL cytotoxicity but 
retained cytotoxicity at higher concentrations (Figure 8-5). This may be because 
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the alanine substitution fails to introduce a significant structural change to 
abolish ε-toxin’s cytotoxicity. However, mass spectrometry results in Section 
8.3.8 confirmed that the V166A sample was contaminated with Etx-YY protein. 
Contamination analysis suggests that the Etx-YY contaminant was sufficiently 
concentrated to influence V166A’s cytotoxicity profile (Figure 8-7). 
Consequently, it is possible that the Etx-YY contamination was responsible for 
V166A’s cytotoxicity against CHO-hMAL cells at high concentrations. 
Cytotoxicity results from the V166F mutant indicate that the V166 residue is 
critical for ε-toxin’s cytotoxic properties. This suggests that a purified V166A 
sample may demonstrate significantly reduced CHO-hMAL cytotoxicity levels, 
potentially comparable to the V166F sample. These results further suggest that 
the BOG binding site is important for ε-toxin’s cytotoxicity. 
The V72A mutant failed to reduce CHO-hMAL cytotoxicity at all concentrations 
used in the assay (Figure 8-5). This may be because the alanine substitution 
fails to introduce a significant structural change to influence ε-toxin’s cytotoxicity 
potentially because the BOG binding site remains fully functional. This is 
supported by the V72F mutant that targeted the same residue but demonstrated 
significantly reduced CHO-hMAL cytotoxicity compared to the V72A sample.  
This suggests that the V72 residue is critical for ε-toxin’s cytotoxic properties but 
that the type of amino acid substitution is critical in influencing the cytotoxicity of 
ε-toxin. Mass spectrometry results in Section 8.3.8 revealed that the V72A 
sample was contaminated with the Etx-YY protein. However, the contamination 
was not sufficiently concentrated to explain V72A’s cytotoxicity profile (Figure 
8-7)(Equation 2). Although the Etx-YY contaminant could have impacted the 
results, the data suggests that the V72A mutation fails to introduce a significant 
structural change to influence ε-toxin’s cytotoxicity. However, due to the Etx-YY 
contaminant, future experiments are required to re-purify and test the V72A 
sample in order to confirm its effect on ε-toxin cytotoxicity. 
The cytotoxicity data demonstrated a clear disparity in the effectiveness of 
different amino acid substitutions. Alanine substitutions for the V72 and V166 
residues demonstrated poor levels of cytotoxicity reduction; however, 
phenylalanine substitutions demonstrated strong levels of cytotoxicity reduction. 
These data suggest that the type of amino acid substitution is critical in 
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influencing ε-toxin’s cytotoxicity. This is potentially related to the physiochemical 
properties of these different amino acids.  
Alanine and valine share structural similarities resulting in both amino acids 
possessing similar molecular weights and hydrophobicity characteristics. This 
may result in an alanine substitution being inconsequential (Table 8-9). 
Furthermore, alanine rarely exhibits steric effects meaning that it is unlikely to 
change a protein’s conformation or reactivity [144]. This suggests that the V72A 
and V166A substitutions may be unable to change the BOG binding site 
structure, and may explain why they were unsuccessful. Phenylalanine also 
shares similar hydrophobicity and structural characteristics but possesses a 
larger molecular weight due to the presence of an aromatic ring (Table 8-9). 
This bulkier aromatic side chain will result in a greater steric effect within the 
BOG binding site structure. This steric effect could have prevented BOG binding 
in the V72F and V166F samples, and therefore explain why phenylalanine was 

















aromatic 2.8 165.9 
Valine 
 
Nonpolar 4.2 117.15 
*Hydropathy Index: a number representing the hydrophobic or 
hydrophilic properties of the side-chain of an amino acid [145] 
Table 8-9 - Physiochemical properties of alanine, phenylalanine and valine 
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[146]. 
The results presented within Project 1 largely support the hypothesis. Despite 
contamination of the V72A, V166A and V166F samples, the cytotoxicity data of 
all seven ε-toxin mutants demonstrated reduced CHO-hMAL cytotoxicity 
compared to the Etx-YY background (Figure 8-6). This decreased cytotoxicity 
suggests that there could be reduced binding between the ε-toxin mutants and 
the CHO-hMAL cells. One possible explanation for this is that the mutations 
prevent direct or indirect interactions between the BOG binding domain and the 
putative MAL receptor. However, there is a risk that the folding of the ε-toxin 
mutants is incorrect. In this case, the cytotoxicity data obtained in Figure 8-6 
would not be representative of the ε-toxin mutations. Protein folding analysis of 
the ε-toxin mutants is therefore required to investigate if the decreased 
cytotoxicity is due to reduced ε-toxin binding or incorrect protein folding. The 
results also reveal a clear disparity between the effectiveness of different amino 
acid substitutions. Consequently, this suggests that the type of amino acid 
substitution is also critical in affecting the BOG binding domain and ε-toxin’s 
cytotoxicity towards CHO-hMAL cells. Notwithstanding these issues, the results 
obtained in this project support the hypothesis statement that: ‘Site directed 
mutagenesis of amino acids within the BOG binding domain will reduce epsilon 
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8.5 FUTURE WORK 
8.5.1 Samples V72A, V166A and V166F 
Mass spectrometry data revealed that the V72A, V166A and V166F samples 
were contaminated (Figure 8-7). V72A and V166A were contaminated with Etx-
YY protein and V166F was cross-contaminated with A168F. The contamination 
in these samples could have affected the cytotoxicity data obtained for these 
samples. Consequently, it is unclear how these mutations affect the cytotoxicity 
of ε-toxin. To resolve this, it is recommended that these samples be repeated, 
checked for contamination and tested for cytotoxicity. The testing of pure V72A, 
V166A and V166F samples will confirm if they can be considered as possible 
vaccine candidates against ε-toxin.  
8.5.2 Samples F92A and T93A 
Data from mutants targeting the V72 and V166 residues suggest that the 
alanine substitutions are ineffective at reducing ε-toxin’s cytotoxicity. Both the 
F92A and T93A samples involved alanine substitutions and demonstrated poor 
levels of cytotoxic protection to CHO-hMAL cells. Consequently, it may be of 
interest to investigate alternative amino acid substitutions for these residues to 
fully confirm their involvement in ε-toxin’s cytotoxicity.  
8.5.3 Samples V72F and A168F 
The A168F and V72F samples both demonstrated strong levels of cytotoxicity 
reduction and were identified as pure samples by the mass spectrometry 
analysis. Several further experiments are required before these mutants can be 
pursued as vaccine candidates against ε-toxin: 
1) The V72F and A168F CT50 concentrations for CHO-hMAL cells 
remain unknown, as they lie beyond the 0.2 mg/ml starting 
concentration used in the cytotoxicity assays (8.2.20). Future 
experiments could investigate the V72F and A168F mutants at 
concentration ranges above 0.2 mg/ml. These experiments would 
identify the CT50 concentrations for these mutants against CHO-
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hMAL cells. 
2) Future cytotoxicity assays could investigate the V72F and A168F 
cytotoxicity profiles in different cell lines. Previous work identified 
that the background Etx-YY protein was non-toxic to MDCK cells. 
However, experimentation is required to confirm that the V72F and 
A168F mutants remain non-toxic to MDCK cells. Previous work also 
identified that the Etx-YY background retained cytotoxicity to ACHN 
cells. It has since been hypothesised that the ε-toxin BOG binding 
site attaches to the NK receptor of ACHN cells to establish 
cytotoxicity [121]. Future work could therefore elucidate whether the 
V72F and A168F mutations targeting the BOG binding site also 
influences ε-toxin’s cytotoxicity against ACHN cells.  
3) The protein folding of the V72F and A168F mutants remain 
unconfirmed. Incorrect folding could affect the protein conformation 
of these mutants that might compromise their cytotoxicity profiles. 
Protein folding analysis can be investigated using circular 
dichrorism, X-ray Crystallography or nuclear magnetic resonance to 
analyse protein folding between the ε-toxin mutant and WT ε-toxin 
[147][148][149]. These methods would confirm if the V72F and 
A168F mutants are correctly folded, and therefore, if the cytotoxicity 
profiles are representative of the introduced mutations.  
8.6 CONCLUSIONS 
Using the method described in this project, several ε-toxin mutagenesis 
samples were successfully expressed purified and analysed for cytotoxicity 
against CHO-hMAL cells. In particular, the V72F, V166F and the A168F 
samples showed at least a 68.8 fold cytotoxicity reduction to CHO-hMAL cells 
and demonstrate significant promise as ε-toxin vaccine candidates. 
Phenylalanine mutants resulted in greater cytotoxicity reductions compared to 
alanine substitutions that may be related to physiochemical differences between 
these amino acids. Mass spectrometry data revealed that the V72A, V166A and 
V166F samples were contaminated. Consequently, future work is required to re-
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purify the contaminated samples and investigate the V72F and A168F mutants 
for protein folding and further analysis in other cell lines.  
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9 PROJECT 2 – SERUM NEUTRALISATION OF Ε-TOXIN 
9.1 PROJECT OBJECTIVES 
In 2012, C. perfringens Type B was isolated in a patient with clinical 
presentations of MS [75]. C. perfringens Type B secretes ε-toxin that bypasses 
the blood brain barrier and demyelinates axons in ruminant animals. These 
demyelination activities show striking similarities to the pathology of MS. Recent 
research identified greater ε-toxin immunoreactivity in MS patients compared to 
controls [75]. This suggested that MS patients have previous exposure to ε-
toxin that may have contributed to their disease. Consequently, the aim of this 
study was to investigate whether the anti-ε-toxin antibodies present in MS sera 
could bind and neutralise ε-toxin. To achieve this, ε-toxin was mixed with sera 
and incubated with CHO cells expressing the putative MAL binding receptor for 
ε-toxin [85]. Neutralisation of ε-toxin by serum antibodies would confer cytotoxic 
protection to the CHO-hMAL cells that can be quantified using a cytotoxicity 
assay.  
The methods to achieve the objectives of Project 2 are as follows: 
1) Identify ε-toxin’s cytotoxic 50% dose against CHO-hMAL cells using 
a cytotoxicity assay.  
2) Demonstrate neutralisation of ε-toxin using previously obtained anti-
ε-toxin antibodies. Antibody/ε-toxin solutions are incubated with 
CHO-hMAL cells and checked for cytotoxicity. 
3) Investigate neutralisation of ε-toxin using sera obtained from MS, 
CIS and control patients. Sera/ ε-toxin solutions are incubated with 
CHO-hMAL cells and checked for cytotoxicity.  
4) Sera neutralisation capabilities against ε-toxin can be compared.  
These data will be used in conjugation with research from another 
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9.1.1 Project Hypothesis 
Compared to control sera, MS and CIS patient sera will confer greater cytotoxic 
protection to CHO-hMAL cells against ε-toxin due to the presence of anti ε-toxin 
antibodies. 
9.2 MATERIALS AND METHODS 
This section contains a detailed account of the different materials and methods 
used to complete all individual experiments undertaken in Project 2.  
9.2.1 CHO-hMAL Culturing 
CHO-hMAL cells were resuscitated and grown in T25 and T75 tissue culture 
flasks, or for assays as described previously (Sections 8.2.17, 8.2.18, 8.2.19). 
9.2.2 SDS-PAGE – Wild Type ε-toxin Trypsin Activation 
SDS-PAGE analysis was used to check WT ε-toxin trypsin activation and was 
completed as previously described (Section 8.2.20). 
9.2.3 Wild Type ε-toxin Cytotoxicity Assay  
A CytoTox96® Non-Radioactive LDH Cytotoxicity Assay (Promega) was used 
to calculate the cytotoxic 50% dose of WT ε-toxin against CHO-hMAL cells as 
previously described (Section 8.2.20). 
9.2.4 Wild Type ε-toxin Neutralisation Using an Anti-ε PoAb 
WT ε-toxin neutralisation using an anti-ε-toxin was analysed with a CytoTox96® 
Non-Radioactive LDH Cytotoxicity Assay following the manufacturer’s 
instructions (Promega). WT ε-toxin neutralisation was completed using an anti-
ε-toxin polyclonal rabbit antibody (anti-ε PoAb). Briefly, WT ε-toxin concentration 
(mg/ml) was identified using a NanoDrop 1000 (BioRad) and converted to molar 
concentration (Equation 1). WT ε-toxin was diluted to a starting concentration of 
50xCT50 with PBS. 10 µL of inactivated 50 µM ε-toxin was mixed with 10 µl of 
4xLDS Buffer for SDS PAGE analysis (Section 9.2.2). Following WT ε-toxin 
trypsin activation, 10 µL of activated ε-toxin was mixed with 10 µl of 4xLDS 
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Buffer for SDS PAGE analysis (Section 9.2.2). 
Using a 96-well V-bottomed plate, an anti-ε PoAb was diluted in PBS through a 
two-fold dilution. Wells were mixed with equal volumes of activated ε-toxin 
(50xCT50) and incubated at room temperature for one hour. Using a previously 
seeded 96 well plate (Section 8.2.19), 100 µl of old cell media was replaced 
with 80 µl of pre-warmed DMEM. 20 µl of each ε-toxin and anti-ε PoAb solution 
was transferred to respective wells on the seeded plate. 20 µl of the positive 
and negative controls were each added to three control wells (Table 9-1). The 
seeded 96-well plate was incubated at 37°C, 5% CO2 for three hours. Following 
incubation, 50 µl of cell culture medium from all control and experimental wells 
was transferred to a fresh 96-well plate and mixed with 50 µl of reconstitution 
substrate mix.  Following a 30 minute incubation in the dark at room 
temperature, the wells were mixed with 50 µl of stop solution and cytotoxicity 
measured at 490 nm using a microplate reader (BioRad). The mean PBS OD 
score was subtracted from all experimental values and data analysed for 
neutralisation activity. 




0.1X Triton X Positive 
1xCT50 WT- ε-toxin Positive 
Table 9-1 - Experimental controls employed for the LDH assay 
investigating WT ε-toxin neutralisation using an anti-ε PoAb  
9.2.5 Serum Neutralisation of Wild Type ε-toxin 
WT ε-toxin neutralisation using human sera was analysed with a CytoTox96® 
Non-Radioactive LDH Cytotoxicity Assay following the manufacturer’s 
instructions (Promega). Briefly, WT ε-toxin concentration (mg/ml) was identified 
using a NanoDrop 1000 (BioRad) and converted to molar concentration 
(Equation 1). WT ε-toxin was diluted to a starting concentration of 10xCT50 with 
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PBS. 10 µL of the inactivated 50 µM ε-toxin was mixed with 10 µl of 4xLDS 
Buffer for SDS PAGE analysis (Section 9.2.2). Following WT ε-toxin trypsin 
activation, 10 µL of activated ε-toxin was mixed with 10 µL of 4xLDS Buffer for 
SDS PAGE analysis (Section 9.2.2). 
Using a 96-well V-bottomed plate, equal volumes of human sera and activated 
ε-toxin (10xCT50) were mixed and incubated at room temperature for one hour. 
Using a previously seeded 96 well plate (Section 8.2.19), 100 µl of old cell 
media was replaced with 80 µl of pre-warmed DMEM. 20 µl of the serum/ WT ε-
toxin solution was transferred to respective wells on the seeded plate. 20 µl of 
the positive and negative controls were each added to three control wells (Table 
9-2). The 96-well plate was incubated at 37°C, 5% CO2 for three hours. 
Following incubation, 50 µl of cell culture medium from all control and 
experimental wells was transferred to a fresh 96-well plate and mixed with 50 µl 
of reconstitution substrate mix. Following a 30 minute incubation in the dark at 
room temperature, the wells were mixed with 50 µl of stop solution and 
cytotoxicity measured at 490 nm using a microplate reader (BioRad). The mean 
PBS negative control was subtracted from all experimental values and data 
analysed for neutralisation activity. 








0.1X Triton X Positive 
1xCT50 WT ε-toxin Positive 
Table 9-2 - Experimental controls employed for the LDH assay 
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9.2.6 Serum Cytotoxicity to CHO-hMAL Cells 
A CytoTox96® Non-Radioactive LDH Cytotoxicity Assay (Promega) was used 
to analyse serum cytotoxicity to CHO-hMAL cells following the manufacturer’s 
instructions.  
Using a 96-well V-bottomed plate, equal volumes of human sera (20 samples) 
and PBS were mixed together. Using a previously seeded 96 well plate (Section 
8.2.19), 100 µl of old cell media was replaced with 80 µl of pre-warmed DMEM 
without FBS. 20 µl of the serum-PBS mix was added to seeded wells and 20 µl 
was added to non-seeded wells. 20 µl of the positive and negative controls 
were each added to three seeded control wells (Table 9-3). The 96-well plate 
was incubated at 37°C, 5% CO2 for three hours. Following incubation, 50 µl of 
culture medium from all control and experimental wells was transferred to a 
fresh 96-well plate and mixed with 50 µl of reconstitution substrate mix. 
Following a 30 minute incubation in the dark at room temperature, the wells 
were mixed with 50 µL of stop solution and cytotoxicity measured at 490 nm 
using a microplate reader. (BioRad). OD scores for sera in seeded and non-
seeded wells were compared to identify serum cytotoxicity to CHO-hMAL cells. 




0.1X Triton X Positive 
Table 9-3 - Experimental controls employed for the LDH Assay 
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9.2.7 Sera LDH Activity 
Sera LDH levels were analysed using a CytoTox96® Non-Radioactive LDH 
Cytotoxicity Assay following the manufacturer’s instructions (Promega). Briefly, 
15 µl of each human serum sample was transferred aseptically to wells on a 
non-seeded 96-well plate and mixed with 15 µl of PBS. 20 µl of the serum-PSB 
solution was added to 80 µl of DMEM without FBS and serum colour measured 
at 490 nm using a micro-plate reader (BioRad). 20 µl of the positive and 
negative control samples were each added to three wells containing 80 µl of 
DMEM without FBS (Table 9-4).  
50 µl of experimental and control samples were transferred to a new 96-well 
plate and mixed with 50 µl of reconstitution substrate mix. Following a 30 
minute incubation in the dark at room temperature and sera LDH activity 
measured at 490 nm using a microplate reader (BioRad). Serum colour levels 
were subtracted from experimental values and data compared with the controls.  




LDH Positive Control 
(Promega) 
Positive 
Table 9-4 - Experimental controls employed for the LDH assay 
investigating serum LDH activity. 
9.2.8 LDH Isoenzyme Testing (Great Ormond Street Hospital) 
Selected CIS and control serum samples were sent to Great Ormond Street 
Hospital (GOSH) for LDH isoenzyme analysis by electrophoresis. Briefly, 5 µl 
samples were loaded onto a rinsed pre-cast 6.5% polyacrylamide gel in a tank-
containing buffer (2.4 g Tris base, 11.6 g glycine/litre). Electrophoresis was 
completed at 12 mA for 90 minutes. The gel was removed and washed in 
developer solution (H2O-18.4 ml, 1M-Tris 4 ml, tetrazolium-blue 12 ml, 
phenzinemethosulphate 4 ml, Na-lactate 4 ml and NAD 1.3 mL at 40°C for 20 
minutes. The gel was washed with water and visualised. Isoenzyme 
quantification was completed by measuring the pixel density for each 
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isoenzyme band. The density of each isoenzyme band was calculated and 
expressed as a percentage for the whole sample [150]. 
9.2.9 MTT Assay – Wild Type ε-toxin Cytotoxicity Assay  
The cytotoxic 50% dose of WT ε-toxin against CHO-hMAL cells was calculated 
using a CytoTox96® Non-Radioactive MTT Assay following the “Same Day 
Method” as per the manufacturer’s instructions (Promega). Briefly, WT ε-toxin 
concentration (mg/ml) was identified using a NanoDrop 1000 (BioRad) and 
converted to molar concentration (Equation 1). ε-toxin mutants were diluted to a 
starting concentration of 50 µM using PBS. 10 µl of the inactivated 50 µM ε-
toxin was mixed with 10 µl of 4xLDS Buffer for SDS PAGE analysis (Section 
9.2.2). Following WT ε-toxin trypsin activation, 10 µl of activated ε-toxin was 
mixed with 10 µl of 4xLDS Buffer for SDS PAGE analysis (Section 9.2.2). Using 
a 96-well V-bottomed plate, activated ε-toxin mutants were diluted in PBS 
through a two-fold dilution.  
Using a previously seeded 96 well plate, old cell media was replaced with 80 µl 
of pre-warmed DMEM. 20 µl of each dilution was transferred to their respective 
wells on the seeded plate. 20 µl of the control samples were each added to 
three seeded control wells (Table 9-5). The 96-well plate was incubated at 
37°C, 5% CO2 for three hours. Cell media was replaced with 85 µl of DMEM 
and 15 µl of MTT dye solution. Following a further four hour incubation at 37°C, 
5% CO2, 100 µl of stop/solubilisation solution was added to all wells and 
incubated at room temperature for one hour. Cytotoxicity was measured at 490 
nm using a microplate reader (BioRad). The mean PBS value was subtracted 
from all experimental values and data analysed for neutralisation activity. The 
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Wild Type ε-toxin 




0.1X Triton X Positive 
Table 9-5 - Experimental controls employed for the MTT Assay 
investigating Wild Type ε-toxin cytotoxicity to CHO-hMAL cells. 
9.2.10 MTT Assay – Wild Type ε-toxin Neutralisation using Anti-ε PoAb  
The cytotoxic 50% dose of ε-toxin against CHO-hMAL cells using a 
CytoTox96® Non-Radioactive MTT Assay following the “Same Day Method” as 
per the manufacturer’s instructions (Promega). Briefly, WT ε-toxin concentration 
(mg/ml) was identified using a NanoDrop 1000 (BioRad) and converted to molar 
concentration (Equation 1). WT ε-toxin was diluted to a starting concentration of 
10xCT50 with PBS. 10 µl of the inactivated 50 µM ε-toxin was mixed with 10 µl of 
4xLDS Buffer for SDS PAGE analysis (Section 9.2.2). Following WT ε-toxin 
trypsin activation, 10 µl of activated ε-toxin was mixed with 10 µl of 4xLDS 
Buffer for SDS PAGE analysis (Section 9.2.2). 
Using a 96-well V-bottomed plate, an anti-ε PoAb was diluted in PBS through a 
two-fold dilution. Each well was mixed with equal volumes of activated ε-toxin 
(10xCT50) and incubated at room temperature for one hour. Using a previously 
seeded 96 well plate (Section 8.2.19), 100 µl of old cell media was replaced 
with 80 µl of pre-warmed DMEM. 20 µl of each two-fold dilution was transferred 
to respective wells on the seeded plate diluting the activated ε-toxin to 1xCT50. 
20 µl of the control samples were each added to three seeded control wells 
(Table 9-6). The 96-well plate was incubated at 37°C, 5% CO2 for three hours. 
Cell media was replaced with 85 µl of DMEM and 15 µl of MTT dye solution. 
Following a four hour incubation at 37°C, 5% CO2, 100 µl of stop/solubilisation 
solution was added to all wells and incubated at room temperature for one hour. 
Cytotoxicity was measured at 490 nm using a microplate reader (BioRad). The 
mean PBS value was subtracted from all experimental values and data 
analysed for neutralisation activity. 
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0.1X Triton X Positive 
1xCT50 WT- ε-toxin Positive 
Table 9-6 - Experimental controls employed for the MTT Assay 
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9.3 RESULTS 
This section describes the individual results obtained from all experiments 
completed in Project 2. 
9.3.1 Wild Type ε-toxin CT50 Calculation  
Using the LDH cytotoxicity assay, WT ε-toxin’s cytotoxic 50% (CT50) dose 
against CHO-hMAL cells was determined through a two-fold dilution (Figure 
9-1). Non-linear regression analysis identified the WT ε-toxin CT50 as 0.32 µM 
against CHO-hMAL cells. 
 
Figure 9-1 - Illustrates optical density measuring mean LDH release from 
CHO-hMAL cells. Cells were incubated with WT ε-toxin, a PBS negative 
control or TritonX positive control. WT ε-toxin was diluted through a two-
fold dilution starting at a concentration of 1.7 µM. Results are from two 
replicates measured at OD490nm. The error bars represent the standard 
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9.3.2 Wild Type ε-toxin Neutralisation Using an Anti-ε PoAb 
WT ε-toxin neutralisation was demonstrated with an anti-ε PoAb using an LDH 
cytotoxicity assay. Figure 9-2 illustrates that WT ε-toxin (1xCT50) cytotoxicity 
increases to 1xCT50 positive control levels as the anti-ε PoAb concentration 
decreases. Complete WT ε-toxin neutralisation was observed between anti-ε 
PoAb concentrations of 0.9 and 0.225 mg/ml.  
 
Figure 9-2 - Illustrates optical density measuring mean LDH release from 
CHO-hMAL cells. Cells were incubated with WT ε-toxin (1xCT50) mixed with 
anti-ε-PoAb, a PBS negative control or TritonX positive control. The anti-ε-
PoAb was diluted through a two-fold dilution starting at a concentration of 
0.9 mg/ml. Results shown are from two replicates measured at OD490nm. 
The error bars represent the standard error of the mean. 
9.3.3 Wild Type ε-toxin Serum Neutralisation Assay (Sample Group 1) 
WT ε-toxin neutralisation by control, CIS and MS sera was completed using an 
LDH cytotoxicity assay. Sera were mixed with a 1xCT50 dose of WT epsilon 
toxin and cytotoxicity results were normalised against the 1xCT50 positive 
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LDH activity compared to the 1xCT50 positive control. Evidence of ε-toxin 
neutralisation by control, CIS and MS sera was not observed.  
 
Figure 9-3 - Illustrates optical density measuring mean LDH release from 
CHO-hMAL cells. Cells were incubated with WT ε-toxin (1x CT50), mixed 
with control, CIS or MS patient sera, WT ε-toxin (1x CT50) positive control 
and WT ε-toxin (1x CT50) mixed with a neutralising concentration of anti-ε-
PoAb as the negative control. Data shown was normalised against the 
1xCT50 positive control and adjusted for serum colour variation. Results 
are from two replicates of sera samples in Appendix C.1 measured at 
OD490nm. The error bars represent the standard error of the mean.  
9.3.4 Serum Cytotoxicity to CHO-hMAL cells (Sample Group 1) 
Serum mediated cytotoxicity to CHO-hMAL cells was investigated using an LDH 
cytotoxicity assay.  Figure 9-4 illustrates consistent LDH levels between the 
control, CIS and MS sera groups and the PBS negative control. These data 
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Figure 9-4 - Illustrates optical density measuring mean LDH release from 
CHO-hMAL cells incubated with control, CIS or MS sera compared to a 
PBS negative control. Results shown are from two measurements 
recorded at OD490nm of sera samples listed in Appendix C.1. The error bars 
represent the standard error of the mean. 
9.3.5 Serum LDH Levels (Sample Group 2) 
Sera LDH activity was investigated using an LDH assay. Data in Figure 9-5 
shows that all three sera groups demonstrated increased LDH activity 
compared to the PBS negative control. The CIS sera group demonstrated the 
most LDH activity followed by the control group and lastly the MS group. The 
difference in LDH activity between the CIS and Control sera groups and the CIS 
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Figure 9-5 - Illustrates optical density measuring mean LDH activity in 
control, CIS and MS sera compared to a PBS negative control. Statistically 
significant differences were identified between control and CIS sera at 
P≤0.01 and between CIS and MS sera at P≤0.05. Results shown are from 
two measurements recorded at OD490nm of sera samples listed in Appendix 
C.2. Data analysed using the Kolmogorov-Smirnov unpaired statistical 
test. The error bars represent the standard error of the mean.  
9.3.6 GOSH - LDH Isoenzymes 
Differences in sera LDH activity between control and CIS sera (Section 9.3.5) 
were investigated by GOSH using an LDH isoenzyme electrophoresis assay. 
Figure 9-6 illustrates the mean percentage LDH isoenzyme level present in 
control and CIS sera. Elevated LDH isoenzyme 1 and 4 levels were observed in 
CIS patients compared to control patients. However, LDH isoenzymes 2, 3 and 
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Figure 9-6 - Illustrates mean percentage LDH Isoenzyme levels in CIS and 
control sera groups. The experiment was performed using an LDH 
isoenzyme electrophoresis assay completed by GOSH. Three sera 
samples were tested for both the CIS (CIS300, CIS302, CIS314) and control 
group (BUH228, BUH236, BUH239). Results shown are the mean LDH 
isoenzyme level of each sera group obtained from one measurement at 
OD490nm. The error bars represent the standard error of the mean of the 
three samples analysed for the control or CIS sera group.  
9.3.7 Great Ormond Street Hospital LDH Isoenzyme Data vs. LDH Assay 
Data 
Sera LDH levels were compared between the LDH cytotoxicity assay results (X-
axis) and GOSH LDH Isoenzyme results (Y-axis) to check for reproducibility 
(Figure 9-7). The plotted data from both assays followed a line of best fit 
showing that the LDH assay yielded similar sera LDH results compared to the 
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Figure 9-7 - Comparing LDH measurements of sera samples analysed 
using the LDH cytotoxicity assay (X-axis) and the GOSH LDH Isoenzyme 
Assay (Y-axis). Results shown are the mean LDH levels of the three CIS 
and control sera samples from both assays. A line of best fit has been 
plotted. 
9.3.8 Serum LDH Levels Grouped According to Sample Origin 
Serum LDH results (Section 9.3.5) were categorised according to their patient 
group and hospital of origin to investigate if differences in serum handling 
conditions at different hospitals were affecting sera LDH results. Figure 9-8 
shows that serum LDH results varied considerably between corresponding sera 
groups obtained from different hospitals. Statistically significant sera LDH 
results were observed between the Exeter Research Innovation Learning and 
Development Centre (RILD) and Exeter Medical School control sera (P≤0.001), 
the Exeter RILD and Barts NHS Trust control sera (P<0.05), the Exeter Medical 
School and Barts NHS Trust control sera (P≤0.0001) and the Exeter Medical 
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Figure 9-8 - Illustrates optical density measuring mean sera LDH activity 
categorised by sera group and hospital origin. Statistically significant 
differences were identified between Exeter RILD and Exeter Medical 
School at P≤0.0001, Exeter Medical School and Barts NHS Trust at 
P≤0.001 and Exeter Medical School and Barts NHS Trust at P≤0.001. 
Results shown are from the mean of sera samples for each patient group 
listed in Appendix C.2 from one measurement at OD490nm. Data analysed 
using the one-way ANOVA statistical test. The error bars represent the 
standard error of the mean.  
9.3.9 Serum LDH Levels (Old Controls vs. New Controls) 
In response to the variable sera LDH results (Section 9.3.8), the sera LDH 
activity of fresh control sera samples obtained from the Exeter serum bank were 
analysed using an LDH cytotoxicity assay. This sera group consisted of 20 
identically treated serum samples that had completed two freeze thaw cycles. 
The fresh control sera demonstrated greater LDH activity compared to 
previously tested samples with reduced LDH variability between individual 
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groups were significant at (P ≤ 0.01). 
 
Figure 9-9 - Illustrates optical density measuring mean LDH levels in 20 
fresh and 20 previously tested control groups. A statistically significant 
difference was identified between the two groups at P≤0.01. Results 
shown are the mean LDH isoenzyme level obtained from one 
measurement at OD490nm of control sera samples listed in Appendix C.2 
and Appendix C.3. Data analysed using the Kolmogorov-Smirnov 
unpaired statistical test. The error bars represent the standard error of the 
mean.  
9.3.10 Serum LDH Levels with Standardised Controls 
The LDH data of fresh control sera (Section 9.3.9) was compared with LDH 
results from previously tested CIS and MS sera samples (Section 9.3.5). Fresh 
control sera demonstrated greater LDH activity against CIS and MS sera 
compared to previously tested controls in Section 9.3.5 (Figure 9-10). 
Comparable LDH levels were observed between the fresh control sera and CIS 
sera (Figure 9-10). The difference in sera LDH activity between the control and 
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Figure 9-10 - Illustrates optical density measuring mean LDH activity in 
control, CIS and MS sera groups compared to a PBS negative control. CIS 
and MS sera groups contain 20 previously tested samples. The control 
group contains 20 fresh sera samples. A statistically significant difference 
was identified between the CIS and MS sera at P≤0.05. Results shown are 
from two measurements recorded at OD490nm of sera samples listed in 
Appendix C.2 and Appendix C.3. Data analysed using the Kolmogorov-
Smirnov unpaired statistical test. The error bars represent the standard 
error of the mean. 
9.3.11 Wild Type ε-toxin CT50 Calculation 
Using the MTT cytotoxicity assay, the WT ε-toxin CT50 dose against CHO-hMAL 
cells was determined through a two-fold dilution (Figure 9-11). Non-linear 
regression analysis identified the WT ε-toxin CT50 dose at 0.112 µM against 
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Figure 9-11 - Illustrates optical density measuring formazan production by 
CHO-hMAL cells. Cells were incubated with a PBS negative control, 
TritonX positive control or a two-fold dilution of WT ε-toxin at a starting 
concentration of 5 µM. Results shown are from three replicates measured 
at OD570nm. The error bars represent the standard error of the mean. 
9.3.12 Wild Type ε-toxin Neutralisation Using an Anti-ε PoAb 
WT ε-toxin neutralisation was completed with an anti-ε PoAb using MTT 
cytotoxicity assay. Figure 9-12 illustrates that decreasing the concentration of 
the anti-ε PoAb corresponds to increased WT ε-toxin (1xCT50) cytotoxicity. 
Evidence of WT ε-toxin neutralisation by the anti-ε PoAb was not observed with 
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Figure 9-12 - Illustrates optical density measuring mean formazan 
production by CHO-hMAL cells. Cells were incubated with a PBS negative 
control, TritonX positive control. WT ε-toxin (1xCT50) positive control or 
WT ε-toxin (1xCT50) mixed with anti-ε-PoAb in a two-fold dilution starting 
at a concentration of 1.26 mg/ml. Results shown are from two replicates 
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9.4 DISCUSSION 
The WT ε-toxin CT50 concentration of 0.32 µM obtained in this project was 
greater than the CT50 concentrations of 3.47 nM and 4.00 nM obtained from 
previous projects (Figure 9-1) [120][85]. The CT50 identified in this project 
illustrates a 92-fold and 8-fold difference compared to the previous CT50 results 
respectively. However, this disparity may be explained by differences in the cell 
lines and assay methods used between these experiments. WT ε-toxin 
neutralisation was demonstrated using an anti-ε PoAb up to 0.281 µg/ml and 
compares closely to a previous experiment where ε-toxin neutralisation was 
demonstrated up to 0.195 µg/ml in MDCK cells (Figure 9-2) [120]. The results 
from both of these assays were obtained from two replicates. Consequently, the 
data presented in Figure 9-1 and Figure 9-2 can only provide the spread of the 
results without a reliable indication of a statistical mean value. The reliability of 
the data and conclusions from these assays would therefore be improved with 
more replicates. Importantly, however, these experiments demonstrated that ε-
toxin cytotoxicity and neutralisation could be detected using an LDH based 
cytotoxicity assay. 
WT ε-toxin sera neutralisation results showed that LDH release was greater in 
the sera groups compared to the ε-toxin positive control (Figure 9-3). These 
results were unusual since both the sera samples and ε-toxin positive control 
were incubated with an equivalent 1xCT50 dose of WT ε-toxin. Therefore it was 
theoretically impossible for cytotoxicity of the sera/toxin solution to be greater 
than the 1xCT50 ε-toxin positive control. Consequently, the neutralisation data 
strongly suggested that an additional factor was contributing to the cytotoxicity 
or LDH content in the assay. In order to obtain useable serum neutralisation 
results, experiments were required to identify the cause of the elevated LDH 
levels.   
Serum samples were first investigated for cytotoxicity against CHO-hMAL cells. 
Sera cytotoxicity would result in elevated LDH activity that would be detected by 
the assay. However, no scientific literature had documented the cytotoxicity of 
human sera to CHO-hMAL cells suggesting that this theory was unlikely to 
explain the results in Figure 9-3. Serum cytotoxicity results in Figure 9-4 
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showed consistent OD readings between the sera groups and the PBS negative 
control. These data suggest that sera from the control, CIS and MS groups 
were non-toxic to CHO-hMAL cells. As a result, the disproportionate LDH 
results obtained in Figure 9-3 were highly unlikely to be due to sera cytotoxicity 
and were probably due to another factor.  
Control, CIS and MS sera samples were therefore analysed for levels of the 
LDH enzyme that could also have contributed to the disproportionate results in 
Figure 9-3. The presence of LDH in human sera is well documented and was 
used to investigate a variety of medical conditions [151][152][153][154]. The 
control, CIS and MS sera all demonstrated elevated LDH results compared to 
the PBS negative control (Figure 9-5). This suggested that sera LDH activity 
was responsible for the disproportionate LDH activity observed in Figure 9-3.  
Elevated sera LDH activity is normally associated with cellular damage caused 
by disease and has been previously used by the healthcare industry to 
investigate illnesses in humans [155][156]. The statistically significant 
differences identified between the control and CIS sera groups as well as the 
CIS and MS sera groups suggest that sera LDH levels may be related to 
differences in tissue damage realised by these conditions (Figure 9-5). 
Consequently, sera LDH activity could potentially be used as a diagnostic 
method to distinguish between MS, CIS and healthy patients. The elevated sera 
LDH activity in CIS sera appears to suggest that there is a possible link 
between the CIS condition and sera LDH activity. It is possible that the CIS sera 
LDH levels are related to neurological damage initiated by the CIS condition. 
However, no previous research has investigated this and therefore it remains 
unclear if sera LDH levels are indicative of CIS. Conversely, MS patients 
demonstrated relatively low sera LDH activity suggesting that it is not linked with 
the condition. However, previous research has reported much greater LDH 
activity in MS sera compared to the results in this experiment [157].  
A possible explanation for this is that the MS sera used in this experiment may 
have been obtained from patients recovering from CNS damage. This is 
particularly plausible for patients suffering from remitting relapsing MS, which is 
characterised by long recovery periods. Patients recovering from tissue damage 
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could possess reduced sera LDH levels potentially explaining the lower MS 
sera LDH results observed in Figure 9-5.  
However, elevated serum LDH activity can be symptomatic of a wide variety of 
disorders and therefore cannot be used to identify the cause or origin of LDH 
within a patient [155]. For example, control sera that was obtained from healthy 
patients, also showed elevated sera LDH activity potentially symptomatic of 
tissue damage (Figure 9-5). This emphasises that sera LDH activity can 
originate from other non-related tissue damage and therefore cannot be linked 
directly to a particular condition. Further analysis was therefore required to 
identify the cause of LDH activity within the CIS and MS patients. This was 
achieved by LDH isoenzyme analysis. The LDH enzyme is composed of four 
separate peptide chains consisting of H or M sub-units. Varying sub-unit 
combinations form the five different LDH tetramers, known as isoenzymes 
(Table 9-7) [158]. These five different LDH isoenzymes demonstrate tissue 
specificity and can therefore be used clinically to localise the source of LDH 
release within a patient [155]. To do this, electrophoresis is used to separate the 
isoenzymes based on their differing electrophoretic mobility’s [155]. The 
proportion of each LDH isoenzyme can then be calculated to estimate the 















LDH-1 H4 19 -30% [155] Cardiac muscle,  
Erthrocytes and 
kidneys 
LDH-2 H3M1 32-48% [155] Cardiac muscle, 
erythrocytes, 
kidneys 
LDH-3 H2M2 12-22% [155] Lung, Pancreas, 
Lymphatic Tissue 
LDH-4 H1M3 5-11% [155] Placenta, 
pancreas 
LDH-5 M4 5-13% [155] Skeletal Muscle 
and Liver 
Table 9-7 - Structural composition, serum concentrations and tissue 
localisation and of the five LDH isoenzymes in humans. 
LDH isoenzyme concentrations in CIS and control sera were largely consistent 
with reported sera concentrations ranges described in Table 9-7 and the typical 
LDH ratios identified in human sera (Figure 9-6) [155]. No statistical differences 
were identified between the control and CIS LDH isoenzyme activity suggesting 
that it cannot be used to differentiate between control and CIS patients. 
Arguably, the mean CIS LDH1 activity of 34% was slightly elevated and may be 
suggestive of tissue damage related to demyelination events characteristic of 
the condition (Figure 9-6). Previous research investigating sera LDH levels in 
MS sera suggested that these abnormal LDH concentrations may also be 
consistent with erythrocyte haemolysis [157][159]. Erythrocytes contain high 
LDH1 concentrations and are more osmotically fragile during acute stages of 
disease in MS patients compared to control patients [160][159]. Consequently, 
these data could suggest that the elevated CIS LDH1 activity in Figure 9-6 is 
suggestive of erythrocyte haemolysis. However, LDH1 activity is common with 
many other medical conditions and therefore may be unrelated to CIS. As a 
result, the data from Figure 9-6 largely suggests that there is no link between 
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sera LDH activity and the development of CIS.  
Furthermore, comparison between the GOSH isoenzyme assay and the LDH 
cytotoxicity assay revealed a line of best fit between the sera LDH results of 
both datasets (Figure 9-7). This demonstrated that the LDH cytotoxicity data 
showed close reproducibility to the GOSH LDH data that was completed 
independently and indicated that the previous LDH cytotoxicity assay results 
were reliable. 
The high LDH variability between the different sera groups in Figure 9-5 
suggested that sera samples within a patient group demonstrated different LDH 
activities. Since sera samples were obtained from four different hospitals it was 
proposed that sera LDH variability may be linked to the sera’s hospital of origin. 
The data demonstrated clear differences in sera LDH activity between control 
and MS sera samples obtained from different hospitals (Figure 9-8). Highly 
significant differences were identified between control sera obtained from the 
Exeter RILD, Exeter Medical School and Barts NHS Trust. Similarly MS sera 
obtained from the Exeter Medical School and Barts NHS Trust was also shown 
to be very statistically different (Figure 9-8). These data strongly suggest that 
sera LDH variability observed in Figure 9-5 is related to the hospital of origin, 
and may be caused by differences in sera handling procedures at these 
different hospitals.  
Scientific literature has documented the susceptibility of the LDH enzyme to 
inactivation by freeze thaw cycles [161][162]. Nema et al. identified that LDH 
activity decreased sharply following successive freeze thaw cycles with 95% 
inactivation of LDH observed after five freeze thaw cycles [161]. This research 
suggests that the sera LDH variability seen in Figure 9-8 could be related to 
differences in the freeze thaw cycle history of each sera sample. Although 
undocumented, it is possible that sera samples used in this project were 
exposed to different numbers of freeze thaw cycles at different hospitals which 
could explain the variable LDH profiles observed in Figure 9-8. Furthermore, 
sera samples were exposed to freeze thaw cycles during the course of the 
project that could also have affected sera LDH activity observed during different 
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experiments in the project.  
The data in Figure 9-8 suggests that sera handling differences between 
different hospitals contributed to variability in LDH levels between sera samples. 
This sera LDH variability could potentially invalidate the previously obtained 
sera LDH and sera neutralisation data (Figure 9-2) and (Figure 9-5). To 
investigate this further, fresh standardised control sera were obtained from the 
Exeter RILD and compared to previously tested control, MS and CIS sera from 
Figure 9-8. The fresh Exeter RILD control sera were subject to identical 
handling and storage conditions and were therefore unaffected by LDH 
inactivation by repeated freeze thaw cycles. Figure 9-9 identified that the fresh 
control sera demonstrated significantly greater LDH activity compared to the 
previously tested control group and increased LDH activity compared to the 
previously tested CIS and MS sera groups (Figure 9-10). In both experiments, 
the fresh control sera demonstrated reduced error bars compared to the other 
sera groups. This suggested that there was reduced LDH variability between 
individual samples, possibly due to the more consistent handling conditions. 
Furthermore, the statistically significant difference between the previously 
tested control sera and CIS sera in Figure 9-5 was not present using the fresh 
control sera in Figure 9-10. This suggested that the LDH levels between the CIS 
and fresh control sera were similar. This therefore negated the previous claim 
that sera LDH activity could be used to diagnose between control, CIS and MS 
patients. As a result, the sera LDH data suggested that the fresh standardised 
sera produced more reliable sera LDH results compared to sera obtained from 
different hospitals. This indicated that consistent sera handling practices were 
required in order to mitigate sera LDH variability between sera samples.    
Sera LDH variability observed in Figure 9-5 suggested that the LDH based 
cytotoxicity assay was inappropriate for investigating sera neutralisation of WT 
ε-toxin. Consequently, an LDH independent MTT assay was employed to 
investigate sera neutralisation of ε-toxin. Using the MTT assay, WT ε-toxin CT50 
dose was calculated at 0.112 µM. This demonstrated a 2.8 fold reduction 
compared to the LDH assay CT50 of 0.322 µM, which suggests that the MTT 
assay is more sensitive to cytotoxicity than the LDH method. The MTT assay 
CT50 concentration also demonstrated a 32 fold and 2.8 fold difference 
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compared to the CT50 concentrations described in other experiments [120][85]. 
However, differences in cell lines and assay could explain this disparity. WT ε-
toxin anti-ε PoAb neutralisation levels remained consistent around the 1xCT50 
positive control for all antibody concentrations used in the MTT assay (Figure 
9-12). This suggested that the anti-ε PoAb failed to neutralise WT ε-toxin. These 
data are in contrast to the previous LDH based WT ε-toxin neutralisation assay 
where strong neutralisation was demonstrated using the same anti-ε PoAb 
solution (Figure 9-2). Furthermore, the WT ε-toxin neutralisation analysis in 
Figure 9-12 was completed using two replicates only. Consequently, the data 
presented in Figure 9-12 can only provide the spread of the results without a 
reliable indication of a statistical mean value. Despite the small spread of the 
results, the reliability of the WT ε-toxin neutralisation analysis shown in Figure 
9-12 would be improved with more replicates.  
Differences between the Triton X positive control and PBS negative control in 
Figure 9-12 suggest that the CHO-hMAL cells were sufficiently confluent for the 
experiment to work. This therefore suggests that cell viability differences were 
not responsible for the observed neutralisation profile. As a result, there are two 
variables that may explain the data observed in Figure 9-12: 
1)  The anti-ε PoAb may have become ineffective for WT ε-toxin 
neutralisation. However, this is considered unlikely since the 
antibody was stored undisturbed at -80°C, and therefore its activity 
should have remained unchanged.   
2) The similarity between the WT ε-toxin neutralisation and 1xCT50 
control data in Figure 9-12 suggests that WT ε-toxin could have 
been overly concentrated for anti-ε PoAb neutralisation. This 
suggests that there may have been a previous error in calculating 
WT ε-toxin’s CT50 concentration in Figure 9-11 or in generating the 
WT ε-toxin + anti-ε PoAb solution for the MTT neutralisation assay. 
Further testing is therefore required to correct the MTT WT ε-toxin neutralisation 
error. Serum neutralisation of WT ε-toxin can then be investigated using the 
MTT assay.  
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Amendments could be made to the sera neutralisation method to produce a 
more robust analysis. For example, the current neutralisation method assumes 
that WT ε-toxin neutralisation levels will be representative of the total anti ε-toxin 
antibodies present in the sera. However, this method does not consider the 
relative differences in antibody levels between the different sera samples. This 
means that, irrespective of their antibody content, sera samples with more 
concentrated antibody levels are more likely to display greater neutralisation 
than those with less concentrated antibody levels. To correct this, antibody 
levels should be analysed for each serum sample. Comparing the sera antibody 
levels with their respective neutralisation results will identify the relative 
neutralisation profile of each serum sample.  
To complete this analysis, purification of the immunoglobulin fraction is required 
for each serum sample. Centrifugation, dextran substrate treatment and 
ammonium sulphate precipitation of the sera samples will first be required to 
remove cell debris, lipoproteins and low molecular weight contaminants from 
the sera respectively [163]. Following resolubilisation, the antibody levels can 
then be compared using affinity chromatography. The most suitable analytical 
method would be to compare serum IgG levels, as this immunoglobulin class 
represents 70-75% of all antibodies present in human serum. This can be 
achieved using Protein G or Protein A purification. These techniques bind IgG 
antibodies based on their high affinity for the protein G and protein A bacterial 
components from the Group G Streptococci and Staphylococcus aureus, 
bacteria respectively [163]. Both methods are highly reliable with purity results 
commonly exceeding 95% [163]. However, while protein G binds to all human 
IgG subclasses, protein A is unable to bind IgG3, and also possesses moderate 
binding affinity for human IgM [164][165]. This suggests that the protein G 
affinity chromatography technique would be the most appropriate technique for 
accurate IgG purification.  
Following antibody purification, the purified IgG concentrations can be 
quantified for all serum samples using the NanoDrop A280 function. IgG levels 
could also be analysed using the Bradford, Lowry, or BCA techniques and 
concentrations identified by comparison to a known IgG standard. Alternatively, 
commercially available indirect human IgG ELISA kits can also be used to 
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quantify sera IgG [166]. The resulting colour change is proportional to the 
sample IgG concentration that can be determined by comparison to a known 
IgG standard. Used in conjugation with previously described purification 
methods, the high specificity of the ELISA technique would further protect 
against any sample contaminants following antibody purification. This method 
would therefore ensure greater accuracy compared to the NanoDrop, BCA, 
Bradford, and Lowry techniques that measure protein concentrations more 
indiscriminately. However, the reportedly high purity results of the affinity 
chromatography methods (>95%) mean that any sample contamination is likely 
to be very low [163]. As a result, the increased accuracy afforded by the ELISA 
technique may not be necessary. The indirect human IgG ELISA can also be 
performed using crude sera samples without any prior purification steps [166]. 
This technique could therefore help to save time by eliminating the need for the 
previously mentioned antibody purification steps. Although faster to complete, 
the ELISA method would be a more expensive technique to perform. 
Furthermore, the IgG quantification procedure would require the testing of a 
large number of sera samples. Consequently, the suitability of each 
quantification method for mass analysis should also be considered. For 
example, the NanoDrop IgG quantification method would most likely require the 
individual testing of each purified sera IgG sample. Whereas the ELISA, 
Bradford, BCA, and Lowry techniques are compatible, or can be adapted, for 
use with a 96-well plate. The latter methods may therefore be more applicable 
for sera IgG quantification due to their increased suitability for mass sample 
analysis.  
Following quantification, sera IgG concentrations can be directly compared to 
their respective MTT assay neutralisation results. WT ε-toxin neutralisation can 
then be better analysed between the different sera groups. This will produce a 
more relevant neutralisation assay that accounts for differences in sera antibody 
levels. 
The sera neutralisation assay results presented in Figure 9-3 demonstrated 
disproportionate cytotoxicity for the control, CIS and MS sera. Consequently, 
the results in Project 2 neither support nor reject the hypothesis. Further 
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investigation in Figure 9-5 suggests that these results were due to sera LDH 
activity interfering with the assay. Consequently, the data from Figure 9-3 
cannot establish if control, MS or CIS patient sera confers cytotoxic protection 
to CHO-hMAL cells against ε-toxin. Furthermore, the project data cannot 
validate the presence of anti ε-toxin antibodies in the different sera groups.  
Results from Figure 9-8 strongly suggest that serum sample variability is due to 
differences in sera handling techniques between different hospitals. This 
suggests that future sera neutralisation analysis should be completed using 
standardised sera samples. Relative differences between sera antibody levels 
should also be considered. Sera LDH interference with the LDH cytotoxicity 
assay also suggests that the alternative MTT assay should be employed for 
future sera neutralisation experiments. With these improvements, future 
experiments will yield a superior analysis to support or reject the project 
hypothesis statement that: “Compared to control sera, MS and CIS patient sera 
will confer greater cytotoxic protection to CHO-hMAL cells against ε-toxin due to 
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9.5 FUTURE WORK 
9.5.1 GOSH LDH Data 
The data in Figure 9-6 revealed increased LDH-1 activity in CIS sera compared 
to control sera. Previous research has suggested that elevated LDH-1 activity 
could be indicative of increased erythrocyte haemolysis in MS sera [157]. 
Erythrocytes are known to contain high LDH-1 concentrations suggesting that 
erythrocyte haemolysis could also be consistent with the elevated CIS LDH-1 
activity observed in Figure 9-6. Consequently, it may be of value to investigate 
haemolysis and erythrocyte fragility in the CIS samples. MS sera was not 
investigated in this assay, however, it may be of value to investigate LDH 
isoenzyme patterns in MS patients and to identify if there are signs of 
erythrocyte haemolysis.  
9.5.2 Standardised Sera Samples 
Data in Figure 9-8 suggests that the sera LDH differences are due to sera 
handling differences between different hospitals. These differences may have 
also influenced the sera antibody levels between different sera samples that 
could have affected the neutralisation data in Figure 9-3. Consequently, these 
data suggest that future sera experiments require fresh standardised sera 
samples obtained from a single hospital to reduce the risk of sera antibody 
variability between serum samples. 
9.5.3 MTT Neutralisation 
The negligible WT ε-toxin neutralisation results in Figure 9-12 suggests there is 
an issue regarding the efficacy of the anti-ε PoAb or in the WT ε-toxin 1xCT50 
concentration. Consequently, further testing is required to identify the error 
responsible for the neutralisation data in Figure 9-12.  Once corrected, the 
project can then advance to the sera neutralisation work using the MTT assay. 
The sera neutralisation assay could be further improved by investigating 
differences in IgG levels between the different serum samples. Comparing sera 
IgG activity with their respective neutralisation results will produce a more 
robust analysis that accounts for differences in sera antibody levels.  
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9.5.4 Conclusions 
The experiments completed in this project aimed to investigate WT ε-toxin 
neutralisation using sera obtained from control, CIS and MS patients. However, 
subsequent work identified that the sera samples contained high levels of the 
LDH enzyme that distorted neutralisation results obtained using the LDH 
cytotoxicity assay. Variability in sera LDH activity indicated that sera LDH levels 
may be useful as a diagnostic biomarker for CIS and MS development. 
However, later experiments identified that this variability was likely introduced 
through differences in sera handling techniques performed between different 
sera banks and hospitals. This variability strongly suggests that sera 
experiments should be completed using fresh standardised sera samples to 
ensure greater experimental control. Consequently, future work should 
concentrate on investigating sera neutralisation of WT ε-toxin using the LDH 
independent MTT assay. However, experiments investigating sera LDH levels 
indicate that erythrocyte haemolysis in CIS and MS patients could be of value to 
investigate further.   
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10 THESIS CONCLUSION 
The research completed as part of this thesis addressed two different topics 
concerning C. perfringens ε-toxin. Project 1 investigated the suitability of several 
SDM targets for development of a next generation veterinary vaccine against ε-
toxin. Using the methods described in this project, SDM was successfully used 
to introduce several mutations into ε-toxin’s BOG binding domain. These 
mutants were subsequently transformed, expressed, purified and analysed for 
cytotoxicity against CHO-hMAL cells. Cytotoxicity analysis demonstrated that all 
seven mutants reduced ε-toxin cytotoxicity towards CHO-hMAL cells, with the 
V72F, V166F and A168F samples resulting in considerable cytotoxicity 
reductions. Despite contamination of the V72A, V166A and V166F samples, the 
results obtained in Project 1 suggest that the BOG binding site is important in 
mediating ε-toxin’s cytotoxicity towards CHO-hMAL cells. This also provides 
further evidence to suggest that the MAL protein is a receptor, or forms part of a 
co-receptor complex for ε-toxin binding. Importantly, the results from this project 
have identified several mutagenesis targets that will advance the development 
of a next generation veterinary vaccine against ε-toxin. This vaccine will help to 
provide a more reliable, controlled and safer ε-toxin immunisation platform 
compared to the current formaldehyde vaccine  
Project 2 investigated MS, CIS and control sera for ε-toxin immunogenicity, to 
identify if sera obtained from MS patients could confer cytotoxic protection to 
CHO-hMAL cells. Using the methods described in this project, ε-toxin’s CT50 
concentration against CHO-hMAL cells was identified. ε-toxin neutralisation was 
then successfully demonstrated using a polyclonal antibody. Sera neutralisation 
analysis of ε-toxin was unsuccessful. Subsequent analysis strongly suggests 
that this was due to sera LDH activity interfering with the cytotoxicity assay. 
Results from further investigation indicate that a more effective sera 
neutralisation analysis could be completed using standardised sera samples 
and using an LDH independent MTT cytotoxicity assay. Relative differences 
between sera antibody levels should also be analysed to better compare the 
neutralisation profile of each sera sample. Consequently, this project was 
unable to establish if MS sera samples possess different ε-toxin 
immunoreactivity levels compared to control of CIS sera. Several improvements 
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have been recommended to provide a more robust analysis that will identify if 
there is a credible link between ε-toxin and the development of MS in humans.  
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APPENDIX A SITE DIRECTED MUTAGENESIS DNA 
SEQUENCES  
 
Figure A - 1 - V72A partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the V72A primers heighted in yellow with 
the V72A amino acid substitution in red. The Y43A and Y209A mutations 
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Figure A - 2 - V72F partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the V72F primers heighted in yellow with 
the V72F amino acid substitution in red. The Y43A and Y209A mutations 
are highlighted in green 
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Figure A - 3 - F92A partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the F92A primers heighted in yellow with 
the F92A amino acid substitution in red. The Y43A and Y209A mutations 
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Figure A - 4 - T93A partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the T93A primers heighted in yellow with 
the T93A amino acid substitution in red. The Y43A and Y209A mutations 
are highlighted in green. 
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Figure A - 5 - V166A partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the V166A primers heighted in yellow with 
the V166A amino acid substitution in red. The Y43A and Y209A mutations 
are highlighted in green. 
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Figure A - 6 - V166F partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the V166F primers heighted in yellow with 
the V166F amino acid substitutions in red. The Y43A and Y209A mutations 
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Figure A - 7 - A168F partial DNA sequence following transformation into 
XL10 Gold E.coli. Sequencing analysis was completed using T7 and T7 
term primers. The figure shows the A168F primers heighted in yellow with 
the A168F amino acid substitutions in red. The Y43A and Y209A mutations 
are highlighted in green. 
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APPENDIX B LIST OF MUTAGENESIS OLIGONUCLEOTIDE 
SEQUENCES 
 





SDM reverse primer 






SDM forward primer 






SDM reverse primer 






SDM forward primer 







SDM reverse primer 
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SDM forward primer 






SDM reverse primer 






SDM forward primer 






SDM reverse primer 






SDM forward primer 






SDM reverse primer 
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SDM forward primer 







SDM reverse primer 







SDM forward primer 
coding for A168F Amino 
acid substitution 
 
Table B - 1 - Illustrates the oligonucleotide primers for used for the site 
directed mutagenesis of ε-toxin  
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APPENDIX C LIST OF SERA SAMPLES 
C.1 HUMAN SERA SAMPLE INFORMATION (SAMPLE GROUP 1) 
Serum ID Patient 
Group 







Exeter Medical School 
Exeter Medical School 
1958 
1972 
PEGN 11 Control F Exeter Medical School 1961 
PEGN 12 Control F Exeter Medical School 1970 
PEGN 13 Control F Exeter Medical School 1963 
PEGN 23 MS F Exeter Medical School 1967 
CIS-301 CIS F Charing Cross Hospital 1944 
CIS-303 CIS F Charing Cross Hospital 1966 
CIS-304 CIS F Charing Cross Hospital 1965 
CIS-305 CIS M Charing Cross Hospital 1969 
CIS-309 CIS F Charing Cross Hospital 1955 
CIS-310 CIS F Charing Cross Hospital 1972 
CIS-311 CIS F Charing Cross Hospital 1996 
BLT-126 MS N/A Barts NHS Trust N/A 
BLT-128 MS M Barts NHS Trust 1967 
BLT-129 MS M Barts NHS Trust 1972 
BLT-134 MS F Barts NHS Trust 1989 
BUH-174 Control M Barts NHS Trust 1941 
BUH-226 Control F Barts NHS Trust 1964 
BUG-241 Control M Barts NHS Trust 1971 
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C.2 HUMAN SERA SAMPLE INFORMATION (SAMPLE GROUP 2) 
Serum ID Patient 
Group 
Gender Hospital of Origin Year of 
Birth 
A1 Control N/A Exeter RILD N/A 
A2 Control F Exeter RILD 1963 
A3 Control F Exeter RILD 1980 
A4 Control F Exeter RILD 1959 
PEGN 11 Control F Exeter Medical School 1961 
PEGN 12  Control F Exeter Medical School 1970 
PEGN 13 Control F Exeter Medical School 1963 
PEGN-14 Control F Exeter Medical School 1970 
PEGN-15 Control F Exeter Medical School 1960 
PEGN-16 Control F Exeter Medical School 1980 
PEGN-17 Control M Exeter Medical School 1968 
PEGN-18 Control F Exeter Medical School 1979 
PEGN-19 Control F Exeter Medical School 1990 
PEGN-20 Control F Exeter Medical School 1965 
PEGN-22 Control F Exeter Medical School 1970 
BUH-228 Control N/A Barts NHS Trust N/A 
BUH-233 Control N/A Barts NHS Trust N/A 
BUH-236 Control N/A Barts NHS Trust N/A 
BUH-239 Control N/A Barts NHS Trust N/A 
BUH-241 Control M Barts NHS Trust 1971 
CIS-300 CIS F Charing Cross 1973 
CIS-301 CIS F Charing Cross 1944 
CIS-302 CIS N/A Charing Cross N/A 
CIS-303 CIS F Charing Cross 1966 
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Serum ID Patient 
Group 
Gender Hospital of Origin Year of 
Birth 
CIS-304 CIS F Charing Cross 1965 
CIS-305 CIS M Charing Cross 1969 
CIS-306 CIS F Charing Cross 1974 
CIS-307 CIS N/A Charing Cross N/A 
CIS-308 CIS N/A Charing Cross N/A 
CIS-309 CIS F Charing Cross 1955 
CIS-310 CIS F Charing Cross 1972 
CIS-311 CIS F Charing Cross 1996 
CIS-312 CIS F Charing Cross 1992 
CIS-313 CIS F Charing Cross 1987 
CIS-314 CIS N/A Charing Cross N/A 
CIS-315 CIS M Charing Cross 1965 
CIS-316 CIS F Charing Cross 1978 
CIS-317 CIS F Charing Cross 1984 
CIS-318 CIS F Charing Cross 1985 
CIS-319 CIS M Charing Cross 1988 
PEGN-1 MS N/A Exeter Medical School N/A 
PEGN-2 MS F Exeter Medical School 1958 
PEGN-3 MS F Exeter Medical School 1972 
PEGN-4 MS N/A Exeter Medical School N/A 
PEGN-6 MS N/A Exeter Medical School N/A 
PEGN-7 MS N/A Exeter Medical School N/A 
PEGN-8 MS N/A Exeter Medical School N/A 
PEGN-9 MS N/A Exeter Medical School N/A 
PEGN-10 MS N/A Exeter Medical School N/A 
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Serum ID Patient 
Group 
Gender Hospital of Origin Year of 
Birth 
PEGN-21 MS N/A Exeter Medical School N/A 
PEGN-23 MS F Exeter Medical School 1967 
BLT-128 MS M Barts NHS trust 1967 
BLT-129 MS M Barts NHS trust 1972 
BLT-130 MS M Barts NHS trust 1952 
BLT-131 MS F Barts NHS trust 1967 
BLT-132 MS N/A Barts NHS trust N/A 
BLT-133 MS F Barts NHS trust 1978 
BUH-135 MS M Barts NHS trust 1943 
BUH-136 MS F Barts NHS trust 1944 
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C.3 HUMAN SERA SAMPLE INFORMATION (SAMPLE GROUP 3) 
Serum ID Patient 
Group 
Gender Hospital of Origin Year of Birth 
A1 Control N/A Exeter RILD N/A 
A2 Control F Exeter RILD 1963 
A3 Control F Exeter RILD 1980 
A4 Control F Exeter RILD 1959 
A5 Control F Exeter RILD 1959 
A6 Control F Exeter RILD 1953 
A7 Control M Exeter RILD 1972 
A8 Control F Exeter RILD 1974 
A9 Control M Exeter RILD 1965 
A10 Control F Exeter RILD 1946 
A11 Control F Exeter RILD 1956 
A12 Control M Exeter RILD 1943 
B1 Control N/A Exeter RILD N/A 
B2 Control F Exeter RILD 1952 
B3 Control M Exeter RILD 1956 
B4 Control N/A Exeter RILD N/A 
B5 Control F Exeter RILD 1965 
B6 Control F Exeter RILD 1947 
B7 Control F Exeter RILD 1961 




Page | 130 
 
BIBLIOGRAPHY 
1. Hailegebreal G. 2017 A Review on Clostridium Perfringens Food 
Poisoning. 4, 104–109. 
2. Matches JR, Liston J, Curran D. 1974 Clostridium perfringens in the 
Environment. Appl. Microbiol. 28, 655–660. 
3. Craven SE. 2000 Colonization of the intestinal tract by Clostridium 
perfringens and fecal shedding in diet-stressed and unstressed broiler 
chickens. Poult. Sci. 79, 843–9. 
4. Paredes-Sabja D, Li J, McClane BA, Sarker MR. In press. Clostridium 
perfringens Sporulation and Sporulation-Associated Toxin Production. In 
The Bacterial Spore: from Molecules to Systems, pp. 331–347. American 
Society of Microbiology. (doi:10.1128/microbiolspec.TBS-0022-2015) 
5. CDC. 2017 Clostridium perfringens. FOOD Saf. See 
https://www.cdc.gov/foodsafety/diseases/clostridium-perfringens.html 
(accessed on 11 July 2017). 
6. McClane BA, Uzal FA, Fernandez Miyakawa ME, Lyerly D, Wilkins T. 
2006 The Enterotoxic Clostridia BT  - The Prokaryotes: Volume 4: 
Bacteria: Firmicutes, Cyanobacteria. In (eds M Dworkin, S Falkow, E 
Rosenberg, K-H Schleifer, E Stackebrandt), pp. 698–752. New York, NY: 
Springer US. (doi:10.1007/0-387-30744-3_22) 
7. Rood JI, McClane BA, Songer JG, Titball RW. 1997 The Clostridia: 
Molecular Biology and Pathogenesis. Elsevier Science.  
8. Freedman JC, Shrestha A, McClane BA. 2016 Clostridium perfringens 
Enterotoxin: Action, Genetics, and Translational Applications. Toxins 
(Basel). 8, 73. (doi:10.3390/toxins8030073) 
9. Hoffmann S, Batz MB, Morris JG. 2012 Annual cost of illness and quality-
adjusted life year losses in the United States due to 14 foodborne 
pathogens. J. Food Prot. 75, 1292–302. (doi:10.4315/0362-028X.JFP-11-
417) 
10. Wormser GP, Stratton C. 2008 Manual of Clinical Microbiology, 9th 
Edition Edited by Patrick R. Murray, Ellen Jo Baron, James H. Jorgensen, 
Marie Louise Landry, and Michael A. Pfaller Washington, DC: ASM Press, 
2007 2488 pp., illustrated. Clin. Infect. Dis. 46, 153–153. 
(doi:10.1086/524076) 
11. Li J, Miyamoto K, Sayeed S, McClane BA. 2010 Organization of the cpe 
locus in CPE-positive clostridium perfringens type C and D isolates. PLoS 
One 5, 465–489. (doi:10.1371/journal.pone.0010932) 
12. Daube G, Simon P, Limbourg B, Manteca C, Mainil J, Kaeckenbeeck A. 
1996 Hybridization of 2,659 Clostridium perfringens isolates with gene 
probes for seven toxins (alpha, beta, epsilon, iota, theta, mu, and 
 
 
Page | 131 
 
enterotoxin) and for sialidase. Am. J. Vet. Res. 57, 496–501. 
13. Kokai-Kun JF, Songer JG, Czeczulin JR, Chen F, McClane BA. 1994 
Comparison of Western immunoblots and gene detection assays for 
identification of potentially enterotoxigenic isolates of Clostridium 
perfringens. J. Clin. Microbiol. 32, 2533–2539. 
14. Doyle MP, Beuchat LR. 2007 Food Microbiology: Fundamentals and 
Frontiers. ASM Press.  
15. Briggs DC, Naylor CE, Smedley JG, Lukoyanova N, Robertson S, Moss 
DS, McClane BA, Basak AK. 2011 Structure of the food-poisoning 
Clostridium perfringens enterotoxin reveals similarity to the aerolysin-like 
pore-forming toxins. J. Mol. Biol. 413, 138–49. 
(doi:10.1016/j.jmb.2011.07.066) 
16. Kitadokoro K et al. 2011 Crystal structure of Clostridium perfringens 
enterotoxin displays features of beta-pore-forming toxins. J. Biol. Chem. 
286, 19549–55. (doi:10.1074/jbc.M111.228478) 
17. Titball RW. 2005 Gas gangrene: an open and closed case. Microbiology 
151, 2821–2828. (doi:10.1099/mic.0.28248-0) 
18. Günzel D, Fromm M. 2012 Claudins and other tight junction proteins. 
Compr. Physiol. 2, 1819–52. (doi:10.1002/cphy.c110045) 
19. Saitoh Y, Suzuki H, Tani K, Nishikawa K, Irie K, Ogura Y, Tamura A, 
Tsukita S, Fujiyoshi Y. 2015 Tight junctions. Structural insight into tight 
junction disassembly by Clostridium perfringens enterotoxin. Science 347, 
775–8. (doi:10.1126/science.1261833) 
20. Robertson SL, Smedley JG, Singh U, Chakrabarti G, Van Itallie CM, 
Anderson JM, McClane BA. 2007 Compositional and stoichiometric 
analysis of Clostridium perfringens enterotoxin complexes in Caco-2 cells 
and claudin 4 fibroblast transfectants. Cell. Microbiol. 9, 2734–55. 
(doi:10.1111/j.1462-5822.2007.00994.x) 
21. Chen J, Theoret JR, Shrestha A, Smedley JG, McClane BA. 2012 
Cysteine-scanning mutagenesis supports the importance of Clostridium 
perfringens enterotoxin amino acids 80 to 106 for membrane insertion 
and pore formation. Infect. Immun. 80, 4078–88. (doi:10.1128/IAI.00069-
12) 
22. Matsuda M, Sugimoto N. 1979 Calcium-independent and dependent 
steps in action of Clostridiumperfringens enterotoxin on HeLa and Vero 
cells. Biochem. Biophys. Res. Commun. 91, 629–636. 
(doi:http://dx.doi.org/10.1016/0006-291X(79)91568-7) 
23. Chakrabarti G, McClane BA. 2005 The importance of calcium influx, 
calpain and calmodulin for the activation of CaCo-2 cell death pathways 




Page | 132 
 
24. Singh U, Van Itallie CM, Mitic LL, Anderson JM, McClane BA. 2000 
CaCo-2 cells treated with Clostridium perfringens enterotoxin form 
multiple large complex species, one of which contains the tight junction 
protein occludin. J. Biol. Chem. 275, 18407–17. 
(doi:10.1074/jbc.M001530200) 
25. Clooten JK, Kruth SA, Weese JS. In press. Genotypic and phenotypic 
characterization of Clostridium perfringens and Clostridium difficile in 
diarrheic and healthy dogs. J. Vet. Intern. Med. 17, 533–540. 
26. Grafarholti D. 2007 The prevalence of Clostridium perfringens enterotoxin 
in dogs with acute diarrhea in southwestern Iceland. , 1–18. See 
https://www.ddd.dk/sektioner/fagdyrlægeforeninger/hundkatsmaedyr/opga
ver/Documents/2007-16 Steinunn Geirsdóttir.pdf (accessed on 17 August 
2017). 
27. Schlegel BJ, Van Dreumel T, Slavić D, Prescott JF. 2012 Clostridium 
perfringens type A fatal acute hemorrhagic gastroenteritis in a dog. Can. 
Vet. J. 53, 555–557. 
28. Titball RW. 1993 Bacterial phospholipases C. Microbiol. Rev. 57, 347–
366. 
29. Takahashi T, Sugahara T, Ohsaka A. 1974 Purification of Clostridium 
perfringens phospholipase C (α-toxin) by affinity chromatography on 
agarose-linked egg-yolk lipoprotein. Biochim. Biophys. Acta - Protein 
Struct. 351, 155–171. (doi:http://dx.doi.org/10.1016/0005-2795(74)90074-
9) 
30. Cavalcanti MTH, Porto T, Porto ALF, Brandi IV, Lima Filho JL de, Pessoa 
Junior A. 2004 Large scale purification of Clostridium perfringens toxins: a 
review. Rev. Bras. Ciências Farm. 40, 151–164. (doi:10.1590/S1516-
93322004000200004) 
31. Canard B, Cole ST. 1989 Genome organization of the anaerobic 
pathogen Clostridium perfringens. Proc. Natl. Acad. Sci. U. S. A. 86, 
6676–80. 
32. Okumura K, Ohtani K, Hayashi H, Shimizu T. 2008 Characterization of 
Genes Regulated Directly by the VirR/VirS System in Clostridium 
perfringens. J. Bacteriol. 190, 7719–7727. (doi:10.1128/JB.01573-07) 
33. Oda M, Terao Y, Sakurai J, Nagahama M. 2015 Membrane-Binding 
Mechanism of Clostridium perfringens Alpha-Toxin. Toxins (Basel). 7, 
5268–5275. (doi:10.3390/toxins7124880) 
34. Naylor CE, Eaton JT, Howells A, Justin N, Moss DS, Titball RW, Basak 
AK. 1998 Structure of the key toxin in gas gangrene. Nat. Struct. Biol. 5, 
738–46. (doi:10.1038/1447) 
35. Sakurai J, O M. 2011 Effect of Macrolide Antibiotics on Biological 
Activities Induced by Clostridium perfringens Alpha-Toxin. In Gangrene - 
 
 
Page | 133 
 
Current Concepts and Management Options, InTech. 
(doi:10.5772/22404) 
36. Titball RW, Leslie DL, Harvey S, Kelly D. 1991 Hemolytic and 
sphingomyelinase activities of Clostridium perfringens alpha-toxin are 
dependent on a domain homologous to that of an enzyme from the 
human arachidonic acid pathway. Infect. Immun. 59, 1872–1874. 
37. Titball RW, Rubidge T. 1990 The role of histidine residues in the alpha 
toxin of Clostridium perfringens. FEMS Microbiol. Lett. 68, 261–266. 
(doi:10.1111/j.1574-6968.1990.tb13948.x) 
38. Guillouard I, Garnier T, Cole ST. 1996 Use of site-directed mutagenesis 
to probe structure-function relationships of alpha-toxin from Clostridium 
perfringens. Infect. Immun. 64, 2440–4. 
39. Jepson M, Bullifent HL, Crane D, Flores-Diaz M, Alape-Giron A, 
Jayasekeera P, Lingard B, Moss D, Titball RW. 2001 Tyrosine 331 and 
phenylalanine 334 in Clostridium perfringens α-toxin are essential for 
cytotoxic activity. FEBS Lett. 495, 172–177. 
(doi:http://dx.doi.org/10.1016/S0014-5793(01)02385-7) 
40. Alape-Girón A et al. 2000 Identification of residues critical for toxicity in 
Clostridium perfringens phospholipase C, the key toxin in gas gangrene. 
Eur. J. Biochem. 267, 5191–7. 
41. Titball RW, Naylor CE, Basak AK. 1999 The Clostridium perfringens 
alpha-toxin. Anaerobe 5, 51–64. (doi:10.1006/anae.1999.0191) 
42. Bryant AE, Stevens DL. 2010 Clostridial myonecrosis: new insights in 
pathogenesis and management. Curr. Infect. Dis. Rep. 12, 383–91. 
(doi:10.1007/s11908-010-0127-y) 
43. Bryant AE, Chen RY, Nagata Y, Wang Y, Lee CH, Finegold S, Guth PH, 
Stevens DL. 2000 Clostridial gas gangrene. II. Phospholipase C-induced 
activation of platelet gpIIbIIIa mediates vascular occlusion and 
myonecrosis in Clostridium perfringens gas gangrene. J. Infect. Dis. 182, 
808–15. (doi:10.1086/315757) 
44. Bryant AE, Stevens DL. 1996 Phospholipase C and perfringolysin O from 
Clostridium perfringens upregulate endothelial cell-leukocyte adherence 
molecule 1 and intercellular leukocyte adherence molecule 1 expression 
and induce interleukin-8 synthesis in cultured human umbilical vein en. 
Infect. Immun. 64, 358–62. 
45. Stevens DL, Bryant AE. 2002 The role of clostridial toxins in the 
pathogenesis of gas gangrene. Clin. Infect. Dis. 35, 93–100. 
(doi:10.1086/341928) 
46. Bryant AE, Chen RY, Nagata Y, Wang Y, Lee CH, Finegold S, Guth PH, 
Stevens DL. 2000 Clostridial gas gangrene. I. Cellular and molecular 
mechanisms of microvascular dysfunction induced by exotoxins of 
 
 
Page | 134 
 
Clostridium perfringens. J. Infect. Dis. 182, 799–807. 
(doi:10.1086/315756) 
47. Peek SF, Semrad SD. 2010 Clostridial myonecrosis in horses. Equine 
Vet. Educ. 14, 163–168. (doi:10.1111/j.2042-3292.2002.tb00162.x) 
48. Goossens E, Valgaeren BR, Pardon B, Haesebrouck F, Ducatelle R, 
Deprez PR, Van Immerseel F. 2017 Rethinking the role of alpha toxin in 
Clostridium perfringens-associated enteric diseases: a review on bovine 
necro-haemorrhagic enteritis. Vet. Res. 48, 1–17. (doi:10.1186/s13567-
017-0413-x) 
49. Gurjar A, Li J, McClane BA. 2010 Characterization of Toxin Plasmids in 
Clostridium perfringens Type C Isolates  . Infect. Immun. 78, 4860–4869. 
(doi:10.1128/IAI.00715-10) 
50. Nagahama M, Ochi S, Oda M, Miyamoto K, Takehara M, Kobayashi K. 
2015 Recent Insights into Clostridium perfringens Beta-Toxin. Toxins 
(Basel). 7, 396–406. (doi:10.3390/toxins7020396) 
51. Theoret JR, Uzal FA, McClane BA. 2015 Identification and 
Characterization of Clostridium perfringens Beta Toxin Variants with 
Differing Trypsin Sensitivity and In Vitro Cytotoxicity Activity. Infect. 
Immun. 83, 1477–1486. (doi:10.1128/IAI.02864-14) 
52. Sakurai J, Nagahama M. 2006 CLOSTRIDIUM PERFRINGENS BETA-
TOXIN: CHARACTERIZATION AND ACTION. Toxin Rev. 25, 89–108. 
(doi:10.1080/15569540500320979) 
53. Ferreira M, Moreira G, Cunha C, Mendonça M, Salvarani F, Moreira Â, 
Conceição F. 2016 Recombinant Alpha, Beta, and Epsilon Toxins of 
Clostridium perfringens: Production Strategies and Applications as 
Veterinary Vaccines. Toxins (Basel). 8, 340. (doi:10.3390/toxins8110340) 
54. Songer JG. 1996 Clostridial enteric diseases of domestic animals. Clin. 
Microbiol. Rev. 9, 216–34. 
55. Hagan WA, Bruner DW, Timoney JF. 1988 Hagan and Bruner’s 
Microbiology and Infectious Diseases of Domestic Animals: With 
Reference to Etiology, Epizootiology, Pathogenesis, Immunity, Diagnosis, 
and Antimicrobial Susceptibility. Comstock Pub. Associates.  
56. Lawrence G, Walker PD. 1976 PATHOGENESIS OF ENTERITIS 
NECROTICANS IN PAPUA NEW GUINEA. Lancet 307, 125–126. 
(doi:10.1016/S0140-6736(76)93160-3) 
57. Ma M, Li J, McClane BA. 2012 Genotypic and Phenotypic 
Characterization of Clostridium perfringens Isolates from Darmbrand 
Cases in Post-World War II Germany. Infect. Immun. 80, 4354–4363. 
(doi:10.1128/IAI.00818-12) 
58. Gurtner C, Popescu F, Wyder M, Sutter E, Zeeh F, Frey J, von Schubert 
C, Posthaus H. 2010 Rapid Cytopathic Effects of Clostridium perfringens 
 
 
Page | 135 
 
Beta-Toxin on Porcine Endothelial Cells. Infect. Immun. 78, 2966–2973. 
(doi:10.1128/IAI.01284-09) 
59. Popescu F, Wyder M, Gurtner C, Frey J, Cooke RA, Greenhill AR, 
Posthaus H. 2011 Susceptibility of primary human endothelial cells to C. 
perfringens beta-toxin suggesting similar pathogenesis in human and 
porcine necrotizing enteritis. Vet. Microbiol. 153, 173–7. 
(doi:10.1016/j.vetmic.2011.02.017) 
60. Nagahama M, Hayashi S, Morimitsu S, Sakurai J. 2003 Biological 
Activities and Pore Formation of Clostridium perfringens Beta Toxin in HL 
60 Cells. J. Biol. Chem. 278, 36934–36941. 
(doi:10.1074/jbc.M306562200) 
61. Autheman D, Wyder M, Popoff M, D’Herde K, Christen S, Posthaus H. 
2013 Clostridium perfringens Beta-Toxin Induces Necrostatin-Inhibitable, 
Calpain-Dependent Necrosis in Primary Porcine Endothelial Cells. PLoS 
One 8, e64644. (doi:10.1371/journal.pone.0064644) 
62. Sakurai J, Nagahama M, Oda M, Tsuge H, Kobayashi K. 2009 
Clostridium perfringens Iota-Toxin: Structure and Function. Toxins 
(Basel). 1, 208–228. (doi:10.3390/toxins1020208) 
63. Uzal FA, Vidal JE, McClane BA, Gurjar AA. 2010 Clostridium Perfringens 
Toxins Involved in Mammalian Veterinary Diseases. open toxinology J. 2, 
24–42. 
64. STILES BG, HALE ML, MARVAUD JC, POPOFF MR. 2002 Clostridium 
perfringens iota toxin: characterization of the cell-associated iota b 
complex. Biochem. J. 367, 801–808. (doi:10.1042/bj20020566) 
65. Gibert M, Petit L, Raffestin S, Okabe A, Popoff MR. 2000 Clostridium 
perfringens Iota-Toxin Requires Activation of Both Binding and Enzymatic 
Components for Cytopathic Activity. Infect. Immun. 68, 3848–3853. 
(doi:10.1128/IAI.68.7.3848-3853.2000) 
66. Richard JF, Mainguy G, Gibert M, Marvaud JC, Stiles BG, Popoff MR. 
2002 Transcytosis of iota-toxin across polarized CaCo-2 cells. Mol. 
Microbiol. 43, 907–17. 
67. Schering B, Bärmann M, Chhatwal GS, Geipel U, Aktories K. 1988 ADP-
ribosylation of skeletal muscle and non-muscle actin by Clostridium 
perfringens iota toxin. Eur. J. Biochem. 171, 225–9. 
68. Tsuge H, Nagahama M, Oda M, Iwamoto S, Utsunomiya H, Marquez VE, 
Katunuma N, Nishizawa M, Sakurai J. 2008 Structural basis of actin 
recognition and arginine ADP-ribosylation by Clostridium perfringens iota-
toxin. Proc. Natl. Acad. Sci. U. S. A. 105, 7399–404. 
(doi:10.1073/pnas.0801215105) 
69. Aktories K, Wegner A. 1992 Mechanisms of the cytopathic action of actin-
ADP-ribosylating toxins. Mol. Microbiol. 6, 2905–8. (doi:10.1111/j.1365-
 
 
Page | 136 
 
2958.1992.tb01749) 
70. Hunter SE, Clarke IN, Kelly DC, Titball RW. 1992 Cloning and nucleotide 
sequencing of the Clostridium perfringens epsilon-toxin gene and its 
expression in Escherichia coli. Infect. Immun. 60, 102–10. 
71. Popoff MR. 2011 Epsilon toxin: a fascinating pore-forming toxin. FEBS J. 
278, 4602–15. (doi:10.1111/j.1742-4658.2011.08145.x) 
72. Gill DM. 1982 Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 
46, 86–94. 
73. Stiles B, Barth G, Barth H, Popoff M. 2013 Clostridium perfringens 
Epsilon Toxin: A Malevolent Molecule for Animals and Man? Toxins 
(Basel). 5, 2138–2160. (doi:10.3390/toxins5112138) 
74. Uzal FA, Kelly WR. 1997 Effects of the intravenous administration of 
Clostridium perfringens type D epsilon toxin on young goats and lambs. J. 
Comp. Pathol. 116, 63–71. (doi:10.1053/jcpa.2001.0514) 
75. Rumah KR, Linden J, Fischetti VA, Vartanian T. 2013 Isolation of 
Clostridium perfringens Type B in an Individual at First Clinical 
Presentation of Multiple Sclerosis Provides Clues for Environmental 
Triggers of the Disease. PLoS One 8, e76359. 
(doi:10.1371/journal.pone.0076359) 
76. Hughes ML, Poon R, Adams V, Sayeed S, Saputo J, Uzal FA, McClane 
BA, Rood JI. 2007 Epsilon-Toxin Plasmids of Clostridium perfringens 
Type D Are Conjugative. J. Bacteriol. 189, 7531–7538. 
(doi:10.1128/JB.00767-07) 
77. Sayeed S, Li J, McClane BA. 2007 Virulence Plasmid Diversity in 
Clostridium perfringens Type D Isolates. Infect. Immun. 75, 2391–2398. 
(doi:10.1128/IAI.02014-06) 
78. Sayeed S, Li J, McClane BA. 2010 Characterization of Virulence Plasmid 
Diversity among Clostridium perfringens Type B Isolates. Infect. Immun. 
78, 495–504. (doi:10.1128/IAI.00838-09) 
79. Bokori-Brown M, Savva CG, Fernandes da Costa SP, Naylor CE, Basak 
AK, Titball RW. 2011 Molecular basis of toxicity of Clostridium perfringens 
epsilon toxin. FEBS J. 278, 4589–4601. (doi:10.1111/j.1742-
4658.2011.08140.x) 
80. Harvard HL, Hunter SEC, Titball RW. 1992 Comparison of the nucleotide 
sequence and development of a PCR test for the epsilon toxin gene of 
Clostridium perfringens type B and type D. FEMS Microbiol. Lett. 97, 77–
81. (doi:10.1111/j.1574-6968.1992.tb05443.x) 
81. Alves GG, Machado de Ávila RA, Chávez-Olórtegui CD, Lobato FCF. 
2014 Clostridium perfringens epsilon toxin: The third most potent bacterial 
toxin known. Anaerobe 30, 102–107. 
 
 
Page | 137 
 
(doi:10.1016/j.anaerobe.2014.08.016) 
82. Manni MM, Sot J, Goñi FM. 2015 Interaction of Clostridium perfringens 
epsilon-toxin with biological and model membranes: A putative protein 
receptor in cells. Biochim. Biophys. Acta - Biomembr. 1848, 797–804. 
(doi:https://doi.org/10.1016/j.bbamem.2014.11.028) 
83. Bullen JJ. 1952 Enterotoxæmia of sheep:Clostridium welchii type D in the 
alimentary tract of normal animals. J. Pathol. Bacteriol. 64, 201–206. 
(doi:10.1002/path.1700640120) 
84. Uzal FA, Songer JG. 2008 Diagnosis of Clostridium perfringens intestinal 
infections in sheep and goats. J. Vet. Diagn. Invest. 20, 253–65. 
(doi:10.1177/104063870802000301) 
85. Rumah KR et al. 2015 The Myelin and Lymphocyte Protein MAL Is 
Required for Binding and Activity of Clostridium perfringens ε-Toxin. 
PLOS Pathog. 11, e1004896. (doi:10.1371/journal.ppat.1004896) 
86. Oliveira DM, Pimentel LA, Pessoa AF, Dantas AFM, Uzal F, Riet-Correa 
F. 2010 Focal symmetrical encephalomalacia in a goat. J. Vet. Diagn. 
Invest. 22, 793–6. (doi:10.1177/104063871002200527) 
87. Tamai E, Ishida T, Miyata S, Matsushita O, Suda H, Kobayashi S, 
Sonobe H, Okabe A. 2003 Accumulation of Clostridium perfringens 
Epsilon-Toxin in the Mouse Kidney and Its Possible Biological 
Significance. Infect. Immun. 71, 5371–5375. (doi:10.1128/IAI.71.9.5371-
5375.2003) 
88. Linden JR, Ma Y, Zhao B, Harris JM, Rumah KR, Schaeren-Wiemers N, 
Vartanian T. 2015 Clostridium perfringens Epsilon Toxin Causes 
Selective Death of Mature Oligodendrocytes and Central Nervous System 
Demyelination. MBio 6, 2513–14. (doi:10.1128/mBio.02513-14) 
89. Lonchamp E et al. 2010 Clostridium perfringens epsilon toxin targets 
granule cells in the mouse cerebellum and stimulates glutamate release. 
PLoS One 5, 1–15. (doi:10.1371/journal.pone.0013046) 
90. Dorca-Arévalo J, Soler-Jover A, Gibert M, Popoff MR, Martín-Satué M, 
Blasi J. 2008 Binding of epsilon-toxin from Clostridium perfringens in the 
nervous system. Vet. Microbiol. 131, 14–25. 
(doi:10.1016/j.vetmic.2008.02.015) 
91. Wioland L et al. 2015 Epsilon toxin from C lostridium perfringens acts on 
oligodendrocytes without forming pores, and causes demyelination. Cell. 
Microbiol. 17, 369–388. (doi:10.1111/cmi.12373) 
92. Miyamoto O. 2000 Clostridium perfringens epsilon toxin causes excessive 
release of glutamate in the mouse hippocampus. FEMS Microbiol. Lett. 
189, 109–113. (doi:10.1016/S0378-1097(00)00262-7) 
93. Finnie JW. 2004 Neurological disorders produced by Clostridium 
perfringens type D epsilon toxin. Anaerobe 10, 145–150. 
 
 
Page | 138 
 
(doi:10.1016/j.anaerobe.2003.08.003) 
94. de la Rosa C, Hogue DE, Thonney ML. 1997 Vaccination schedules to 
raise antibody concentrations against epsilon-toxin of Clostridium 
perfringens in ewes and their triplet lambs. J. Anim. Sci. 75, 2328–34. 
95. Titball RW. 2009 Clostridium perfringens vaccines. Vaccine 27 Suppl 4, 
D44-7. (doi:10.1016/j.vaccine.2009.07.047) 
96. WHO. 2016 WHO Vaccine Safety Basics. Module 2 - Types of Vaccine 
and Adverse Reaction. See http://vaccine-safety-training.org/summary-
module2.html (accessed on 20 June 2017). 
97. Walker PD. 1992 Bacterial vaccines: old and new, veterinary and medical. 
Vaccine 10, 977–90. 
98. Stokka GL, Edwards AJ, Spire MF, Brandt RT, Smith JE. 1994 
Inflammatory response to clostridial vaccines in feedlot cattle. J. Am. Vet. 
Med. Assoc. 204, 415–9. 
99. Lobato FCFF, Lima CGRDRD, Assis RA, Pires PS, Silva ROSS, 
Salvarani FM, Carmo AO, Contigli C, Kalapothakis E. 2010 Potency 
against enterotoxemia of a recombinant Clostridium perfringens type D 
epsilon toxoid in ruminants. Vaccine 28, 6125–7. 
(doi:10.1016/j.vaccine.2010.07.046) 
100. Pelish TM, McClain MS. 2009 Dominant-negative inhibitors of the 
Clostridium perfringens epsilon-toxin. J. Biol. Chem. 284, 29446–53. 
(doi:10.1074/jbc.M109.021782) 
101. Worthington RW, Mülders MS. 1977 Physical changes in the epsilon 
prototoxin molecule of Clostridium perfringens during enzymatic 
activation. Infect. Immun. 18, 549–51. 
102. Miyata S, Matsushita O, Minami J, Katayama S, Shimamoto S, Okabe A. 
2001 Cleavage of a C-terminal Peptide Is Essential for Heptamerization of 
Clostridium perfringens ε-Toxin in the Synaptosomal Membrane. J. Biol. 
Chem. 276, 13778–13783. (doi:10.1074/jbc.M011527200) 
103. Harkness JM, Li J, McClane BA. 2012 Identification of a lambda toxin-
negative Clostridium perfringens strain that processes and activates 
epsilon prototoxin intracellularly. Anaerobe 18, 546–52. 
(doi:10.1016/j.anaerobe.2012.09.001) 
104. Goldstein J, Morris WE, Loidl CF, Tironi-Farinati C, Tironi-Farinatti C, 
McClane BA, Uzal FA, Fernandez Miyakawa ME. 2009 Clostridium 
perfringens epsilon toxin increases the small intestinal permeability in 
mice and rats. PLoS One 4, e7065. (doi:10.1371/journal.pone.0007065) 
105. Li J, Sayeed S, Robertson S, Chen J, McClane BA. 2011 Sialidases affect 
the host cell adherence and epsilon toxin-induced cytotoxicity of 
Clostridium perfringens type D strain CN3718. PLoS Pathog. 7, 
 
 
Page | 139 
 
e1002429. (doi:10.1371/journal.ppat.1002429) 
106. Adamson RH, Ly JC, Fernandez-Miyakawa M, Ochi S, Sakurai J, Uzal F, 
Curry FE. 2005 Clostridium perfringens epsilon-toxin increases 
permeability of single perfused microvessels of rat mesentery. Infect. 
Immun. 73, 4879–87. (doi:10.1128/IAI.73.8.4879-4887.2005) 
107. Buxton D. 1978 Further studies on the mode of action of Clostridium 
welchii type-D epsilon toxin. J. Med. Microbiol. 11, 293–8. 
(doi:10.1099/00222615-11-3-293) 
108. Soler-Jover A, Blasi J, Gómez de Aranda I, Navarro P, Gibert M, Popoff 
MR, Martín-Satué M. 2004 Effect of epsilon toxin-GFP on MDCK cells 
and renal tubules in vivo. J. Histochem. Cytochem. 52, 931–42. 
(doi:10.1369/jhc.4A6254.2004) 
109. Shortt SJ, Titball RW, Lindsay CD. 2000 An assessment of the in vitro 
toxicology of Clostridium perfringens type D epsilon-toxin in human and 
animal cells. Hum. Exp. Toxicol. 19, 108–16. 
(doi:10.1191/096032700678815710) 
110. Uzal FA, Rolfe BE, Smith NJ, Thomas AC, Kelly WR. 1999 Resistance of 
ovine, caprine and bovine endothelial cells to Clostridium perfringens type 
D epsilon toxin in vitro. Vet. Res. Commun. 23, 275–84. 
(doi:10.1023/A:1006362819202) 
111. Türkcan S, Masson J-B, Casanova D, Mialon G, Gacoin T, Boilot J-P, 
Popoff MR, Alexandrou A. 2012 Observing the confinement potential of 
bacterial pore-forming toxin receptors inside rafts with nonblinking Eu(3+)-
doped oxide nanoparticles. Biophys. J. 102, 2299–308. 
(doi:10.1016/j.bpj.2012.03.072) 
112. Petit L, Gibert M, Gillet D, Laurent-Winter C, Boquet P, Popoff MR. 1997 
Clostridium perfringens epsilon-toxin acts on MDCK cells by forming a 
large membrane complex. J. Bacteriol. 179, 6480–7. 
113. Chassin C et al. 2007 Pore-forming epsilon toxin causes membrane 
permeabilization and rapid ATP depletion-mediated cell death in renal 
collecting duct cells. Am. J. Physiol. Renal Physiol. 293, F927-37. 
(doi:10.1152/ajprenal.00199.2007) 
114. Miyata S, Minami J, Tamai E, Matsushita O, Shimamoto S, Okabe A. 
2002 Clostridium perfringens epsilon-toxin forms a heptameric pore within 
the detergent-insoluble microdomains of Madin-Darby canine kidney cells 
and rat synaptosomes. J. Biol. Chem. 277, 39463–8. 
(doi:10.1074/jbc.M206731200) 
115. Knapp O, Maier E, Benz R, Geny B, Popoff MR. 2009 Identification of the 
channel-forming domain of Clostridium perfringens Epsilon-toxin (ETX). 




Page | 140 
 
116. Gil C, Dorca-Arévalo J, Blasi J. 2015 Clostridium Perfringens Epsilon 
Toxin Binds to Membrane Lipids and Its Cytotoxic Action Depends on 
Sulfatide. PLoS One 10, e0140321. (doi:10.1371/journal.pone.0140321) 
117. Fennessey CM, Sheng J, Rubin DH, McClain MS. 2012 Oligomerization 
of Clostridium perfringens epsilon toxin is dependent upon caveolins 1 
and 2. PLoS One 7, e46866. (doi:10.1371/journal.pone.0046866) 
118. Payne DW, Williamson ED, Havard H, Modi N, Brown J. 1994 Evaluation 
of a new cytotoxicity assay for Clostridium perfringens type D epsilon 
toxin. FEMS Microbiol. Lett. 116, 161–167. (doi:10.1111/j.1574-
6968.1994.tb06695.x) 
119. Ivie SE, Fennessey CM, Sheng J, Rubin DH, McClain MS. 2011 Gene-
Trap Mutagenesis Identifies Mammalian Genes Contributing to 
Intoxication by Clostridium perfringens ε-Toxin. PLoS One 6, e17787. 
(doi:10.1371/journal.pone.0017787) 
120. Bokori-Brown M et al. 2014 Clostridium perfringens epsilon toxin mutant 
Y30A-Y196A as a recombinant vaccine candidate against enterotoxemia. 
Vaccine 32, 2682–2687. (doi:10.1016/j.vaccine.2014.03.079) 
121. Bokori-Brown M, Kokkinidou MC, Savva CG, Fernandes da Costa S, 
Naylor CE, Cole AR, Moss DS, Basak AK, Titball RW. 2013 Clostridium 
perfringens epsilon toxin H149A mutant as a platform for receptor binding 
studies. Protein Sci. 22, 650–9. (doi:10.1002/pro.2250) 
122. Schaeren-Wiemers N, Bonnet A, Erb M, Erne B, Bartsch U, Kern F, 
Mantei N, Sherman D, Suter U. 2004 The raft-associated protein MAL is 
required for maintenance of proper axon--glia interactions in the central 
nervous system. J. Cell Biol. 166, 731–42. (doi:10.1083/jcb.200406092) 
123. Antón O, Batista A, Millán J, Andrés-Delgado L, Puertollano R, Correas I, 
Alonso MA. 2008 An essential role for the MAL protein in targeting Lck to 
the plasma membrane of human T lymphocytes. J. Exp. Med. 205, 3201–
13. (doi:10.1084/jem.20080552) 
124. Antón OM, Andrés-Delgado L, Reglero-Real N, Batista A, Alonso MA. 
2011 MAL protein controls protein sorting at the supramolecular activation 
cluster of human T lymphocytes. J. Immunol. 186, 6345–56. 
(doi:10.4049/jimmunol.1003771) 
125. Alonso MA, Weissman SM. 1987 cDNA cloning and sequence of MAL, a 
hydrophobic protein associated with human T-cell differentiation. Proc. 
Natl. Acad. Sci. U. S. A. 84, 1997–2001. 
126. Ramnarayanan SP, Cheng CA, Bastaki M, Tuma PL. 2007 Exogenous 
MAL reroutes selected hepatic apical proteins into the direct pathway in 
WIF-B cells. Mol. Biol. Cell 18, 2707–15. (doi:10.1091/mbc.E07-02-0096) 
127. Morinaga G, Nakamura T, Yoshizawa J, Nishida S. 1965 Isolation of 
Clostridium perfringens Type D from a Case of Gas Gangrene. J. 
 
 
Page | 141 
 
Bacteriol. 90, 826. 
128. Miller C et al. 2004 Fulminant and fatal gas gangrene of the stomach in a 
healthy live liver donor. Liver Transpl. 10, 1315–9. (doi:10.1002/lt.20227) 
129. Greenfield RA, Brown BR, Hutchins JB, Iandolo JJ, Jackson R, Slater LN, 
Bronze MS. 2002 Microbiological, biological, and chemical weapons of 
warfare and terrorism. Am. J. Med. Sci. 323, 326–40. 
130. Anderson PD. 2012 Bioterrorism: toxins as weapons. J. Pharm. Pract. 25, 
121–9. (doi:10.1177/0897190012442351) 
131. Markowitz CE. 2013 Multiple sclerosis update. Am. J. Manag. Care 19, 
s294-300. 
132. Murrell TG, O’Donoghue PJ, Ellis T. 1986 A review of the sheep-multiple 
sclerosis connection. Med. Hypotheses 19, 27–39. 
133. Chandran D, Naidu SS, Sugumar P, Rani GS, Vijayan SP, Mathur D, 
Garg LC, Srinivasan VA. 2010 Development of a Recombinant Epsilon 
Toxoid Vaccine against Enterotoxemia and Its Use as a Combination 
Vaccine with Live Attenuated Sheep Pox Virus against Enterotoxemia and 
Sheep Pox. Clin. Vaccine Immunol. 17, 1013–1016. 
(doi:10.1128/CVI.00013-10) 
134. Agilent Technologies. 2015 QuikChange Lightning Site-Directed 
Mutagenesis Kit - Instruction Manual. , 4–15. See 
http://www.agilent.com/cs/library/usermanuals/public/210518.pdf 
(accessed on 16 November 2016). 
135. Thermo Scientific. 2014 Thermo Scientific - GeneJET Plasmid Miniprep 
Kit. , 4–5. See 
http://www.thermoscientificbio.com/uploadedFiles/Resources/k0502-
product-information.pdf (accessed on 16 February 2015). 
136. Eurofins Genomics. In press. Sample Submission Guide - Value Read 
Tube. , 1. See 
http://www.eurofinsgenomics.eu/media/892645/samplesubmissionguide_
valuereadtube.pdf (accessed on 22 February 2015). 
137. Hall TA. 1999 BioEdit: a user-friendly biological sequence alignment 
editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. 
Ser. 41, 95–98. 




&bd=1#overview (accessed on 16 November 2016). 
139. Studier FW. 2005 Protein production by auto-induction in high-density 
shaking cultures. Protein Expr. Purif. 41, 207–234. 
 
 
Page | 142 
 
(doi:10.1016/j.pep.2005.01.016) 
140. GE Healthcare. 2006 His Gravitrap. GE Healthc. , 1–2. See 
https://www.gelifesciences.com/gehcls_images/GELS/Related 
Content/Files/1314750913712/litdoc11003690_20161014103044.pdf 
(accessed on 16 November 2016). 
141. GE Healthcare. 2007 PD-10 Desalting Columns. GE Healthc. , 1–8. See 
https://www.gelifesciences.com/gehcls_images/GELS/Related 
Content/Files/1478781880316/litdoc52130800_20161110134421.pdf 
(accessed on 16 November 2016). 
142. Olson BJSC, Markwell J. 2007 Assays for Determination of Protein 
Concentration. In Current Protocols in Protein Science, p. 3.4.1-3.4.29. 
Hoboken, NJ, USA: John Wiley & Sons, Inc. 
(doi:10.1002/0471140864.ps0304s48) 
143. Johnson M. 2012 Protein Quantitation. Mater. Methods 2. 
(doi:10.13070/mm.en.2.115) 
144. Cunningham BC, Wells JA. 1989 High-resolution epitope mapping of 
hGH-receptor interactions by alanine-scanning mutagenesis. Science 
244, 1081–5. 
145. Kyte J, Doolittle RF. 1982 A simple method for displaying the hydropathic 
character of a protein. J. Mol. Biol. 157, 105–132. 
(doi:http://dx.doi.org/10.1016/0022-2836(82)90515-0) 
146. ProImmune. 2013 Amino Acid Properties. See 
http://www.thinkpeptides.com/aminoacidproperties.html (accessed on 6 
June 2017). 
147. Unversity of California. 2017 An introduction to circular dichroism 
spectroscopy. See 
https://www.chem.uci.edu/~dmitryf/manuals/Fundamentals/CD 
spectroscopy.pdf (accessed on 7 June 2017). 
148. Clore GM, Gronenborn AM. 1998 NMR structure determination of proteins 
and protein complexes larger than 20 kDa. Curr. Opin. Chem. Biol. 2, 
564–70. 
149. Smyth MS, Martin JHJ. 2000 x Ray crystallography. Mol. Pathol. 53, 8–
14. 
150. University of Semmelweis. 2014 The Isoenzyme Profile of Lactate 
Dehydrogenase. , 1–4. See 
http://semmelweis.hu/biokemia/files/2014/01/EN_lab_LDH_or_BAK-
KOK_20150130.pdf (accessed on 13 January 2017). 
151. Menon MP, Anderson G, Nambiar GK. 1983 Determination of human 
serum lactate dehydrogenase isoenzymes by anion exchange 
chromatography. Anal. Chem. 55, 1385–1390. 
 
 
Page | 143 
 
(doi:10.1021/ac00259a044) 
152. Rothwell DJ, Jendrzejczak B, Becker M, Doumas BT. 1976 Lactate 
dehydrogenase activities in serum and plasma. Clin. Chem. 22, 1024–
1026. 
153. Vesell ES, Bearn AG. 1961 Isozymes of Lactic Dehydrogenase in Human 
Tissues. J. Clin. Invest. 40, 586–591. (doi:10.1172/JCI104287) 
154. Schneider RJ, Seibert K, Passe S, Little C, Gee T, Lee BJ, Mik? V, Young 
CW. 1980 Prognostic significance of serum lactate dehydrogenase in 
malignant lymphoma. Cancer 46, 139–143. (doi:10.1002/1097-
0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8) 
155. Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen-Visser 
M. 1996 Usefulness of lactate dehydrogenase and its isoenzymes as 
indicators of lung damage or inflammation. Eur. Respir. J. 9, 1736–1742. 
(doi:10.1183/09031936.96.09081736) 
156. Huijgen HJ, Sanders GT, Koster RW, Vreeken J, Bossuyt PM. 1997 The 
clinical value of lactate dehydrogenase in serum: a quantitative review. 
Eur. J. Clin. Chem. Clin. Biochem. 35, 569–579. 
157. Lewin A, Hamilton S, Witkover A, Langford P, Nicholas R, Chataway J, 
Bangham CRM. 2016 Free serum haemoglobin is associated with brain 
atrophy in secondary progressive multiple sclerosis. Wellcome Open Res. 
1, 1–23. (doi:10.12688/wellcomeopenres.9967.1) 
158. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. 2016 The Regulation 
and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain 
Tumor. Brain Pathol. 26, 3–17. (doi:10.1111/bpa.12299) 
159. Schauf CL, Frischer H, Davis FA. 1980 Mechanical fragility of 
erythrocytes in multiple sclerosis. Neurology 30, 323–323. 
(doi:10.1212/WNL.30.3.323) 
160. Caspary EA, Sewell F, Field EJ. 1967 Red blood cell fragility in multiple 
sclerosis. Br. Med. J. 2, 610–611. 
161. Nema S, Avis KE. In press. Freeze-thaw studies of a model protein, 
lactate dehydrogenase, in the presence of cryoprotectants. J. Parenter. 
Sci. Technol. 47, 76–83. 
162. Lugovoi VI, Volovel’skaia EL, Grek AM. In press. [Effect of freezing-
thawing on the activity of lactate dehydrogenase isoenzymes]. Ukr. 
biokhimicheskii zhurnal 54, 274–9. 








Page | 144 
 
%3Fla%3Den&usg=AOvVaw1uIQbN11tRNNaK8pMIHjPh (accessed on 
21 February 2018). 
164. LOGHEM E, FRANGIONE B, RECHT B, FRANKLIN EC. 1982 
Staphylococcal Protein A and Human IgG Subclasses and Allotypes. 
Scand. J. Immunol. 15, 275–278. (doi:10.1111/j.1365-
3083.1982.tb00649.x) 
165. Grov A. 1975 HUMAN IgM INTERACTING WITH STAPHYLOCOCCAL 
PROTEIN A. Acta Pathol. Microbiol. Scand. Sect. C Immunol. 83C, 173–
176. (doi:10.1111/j.1699-0463.1975.tb01622.x) 
166. ThermoFisher Scientific. 2017 IgG (Total) Human ELISA Kit. Invitrogen. , 
1–20. See https://www.thermofisher.com/order/catalog/product/BMS2091 
(accessed on 13 March 2018). 
 
